Immunological configuration of ovarian carcinoma: features and impact on disease outcome

Jitka Fucikova 1,2, An Coosemans 3, Sandra Orsulic,4 David Cibula 5, Ignace Vergote,6 Lorenzo Galluzzi,7,8,9 Radek Spisek1,2

ABSTRACT
Epithelial ovarian carcinoma (EOC) is a relatively rare malignancy but is the fifth-leading cause of cancer-related death in women, largely reflecting early, prediagnosis dissemination of malignant disease to the peritoneum. At odds with other neoplasms, EOC is virtually insensitive to immune checkpoint inhibitors, correlating with a tumor microenvironment that exhibits poor infiltration by immune cells and active immunosuppression. Here, we comparatively summarize the humoral and cellular features of primary and metastatic EOC, comparatively analyze their impact on disease outcome, and propose measures to alter them in support of treatment sensitivity and superior patient survival.

INTRODUCTION
Epithelial ovarian carcinoma (EOC) is among the top five causes of cancer-related death in women.1 Indeed, while EOC is relatively rare (it accounts for approximately 2% of all malignancies affecting women, basal cell and squamous cell skin cancers excluded), prognosis is particularly poor as most cases are diagnosed as late-stage invasive disease.1 EOC is traditionally classified into five histological subtypes: high-grade serous ovarian carcinoma (HGSOC), low-grade serous ovarian carcinoma (LGSOCS), mucinous ovarian carcinoma (MOC), endometrioid ovarian carcinoma (EnOC), and ovarian clear cell carcinoma (OCCC), each of which has different cellular origins and molecular profiles.2 The immune contexture and density of tumor-infiltrating T lymphocytes (TILs) vary considerably among different EOCs, being highest in HGSOCs, intermediate in EnOCs, and lowest in LGSOCS, MOCs, and OCCCs.3 Consistent with a role for TIL in EOC progression, a recent study on more than 5900 advanced EOC patients demonstrated a markedly higher risk of mortality for women with MOC and OCCC subtypes as compared with patients with HGSOC and EnOC.4 HGSOC, in which epithelial ovarian cells or secretory cells are present in the mucosa of fallopian tubes, is the most common and aggressive form of EOC.2 Poor outcomes in HGSOC are largely dictated by early dissemination to the peritoneal cavity, especially the omentum, resulting in the formation of metastatic lesions and malignant ascites that ultimately resist currently approved therapeutic strategies.2 A recent study harnessing single-cell RNAseq has provided an even more in-depth resolution of HGSOC, identifying multiple subtypes with differential disease outcome.5–6

The majority of women with EOC achieve indeed complete remission after primary or interval cytoreductive surgery combined with chemotherapy based on a platinum-taxane doublet. Homologous recombination (HR) defects imposed by germline or somatic BRCA1 DNA repair-associated (BRCA1) or BRCA2 mutations are not only key determinants of platinum sensitivity in EOC patients but also provide a strong rationale for maintenance therapy based on poly(ADP-ribose) polymerase (PARP) inhibitors, which is generally associated with improved progression-free survival (PFS).7 Nonetheless, more than 50% of women affected by EOC ultimately experience recurrence with treatment-resistant disease and succumb within 5 years of diagnosis, calling for the urgent development of novel therapeutic approaches to this deadly malignancy.

Successful introduction of immune checkpoint inhibitors (ICIs) for the treatment of multiple tumor types has created enormous expectations around the possibility of harnessing the patient’s own immune system against EOC.8 9 However, compared with other neoplasms, such as non-small cell lung carcinoma and melanoma, EOC is poorly sensitive to ICIs employed as standalone immunotherapeutic agents,9 most likely due to indolent anticancer immunity and robust immunosuppression at baseline.10 In this...
context, a strongly immunosuppressive tumor microenvironment (TME) may considerably contribute to disease progression and metastatic dissemination, calling for the implementation of combinatorial immunotherapeutic strategies beyond immune checkpoint inhibition.\textsuperscript{11} Indeed, additional mechanisms appear to be crucial for the generation of an immunosuppressive contexture in EOC, including increased levels of immunomodulatory cytokines, enzymes and metabolites including interleukin (IL)-6, IL-10, vascular endothelial growth factor A (VEGFA), macrophage migration inhibitory factor (MIF), indoleamine 2,3-dioxygenase 1 (IDO1), arginase 1 (ARG1), and lactate.\textsuperscript{12–15} These factors increase along with disease progression, paralleling the accumulation of immunosuppressive cell types such as CD4^+CD25^+ forkhead box P3 (FOXP3\(^+\)) regulatory T (T\(_{\text{REG}}\)) cells, tumor-associated macrophages (TAMs), tolerogenic dendritic cells (DCs), and myeloid-derived suppressor cells (MDSCs).\textsuperscript{16–19} Thus, multiple immunosuppressive factors quench anticancer immunity in the TME of EOCs, hence representing potential therapeutic targets for drug development.

Importantly, recent technological developments, including modern genomic, transcriptomic and phenotypic assays at single-cell resolution, have provided an in-depth characterization of the cellular and humoral immune contexture of EOC and its impact on disease outcomes. If validated by independent prospective clinical studies, these immunological biomarkers may not only assist in determining the response of patients with EOC to treatment but also enable the adoption of personalized treatment approaches with superior likelihood for success. Here, we present key immunological features of primary versus metastatic EOC and critically discuss their potential value as prognostic and predictive biomarkers.

THE IMMUNE MICROENVIRONMENT IN OVARIAN CARCINOMA

The immunological contexture of both primary and metastatic EOC lesions builds on a complex network of immune and non-immune cells that interact, both physically and via soluble mediators, with each other, with malignant cells and with the extracellular matrix (figure 1).\textsuperscript{20–22} Importantly, while some immune cells, such as T lymphocytes, B cells and DCs, can be found within EOC cell nests, many cellular components of the immune system, such as MDSCs, natural killer (NK) cells, mast cells and neutrophils, are primarily localized at the invasive margin.\textsuperscript{21} Moreover, it became clear that the immunological configurations of primary and metastatic EOC differ considerably from each other,\textsuperscript{20,23} as well as that the degree of primary and metastatic EOC infiltration by immune cells exhibit considerable heterogeneity across patients.\textsuperscript{24–26} In this setting, analytical approaches that go beyond the mere estimation of cellular density in diagnostic biopsies to include spatial localization and functional orientation of the immune compartment of metastatic EOC have identified components of the EOC immune contexture that are linked to improved disease outcome, as discussed here below.\textsuperscript{10,27}

T lymphocytes

An elevated number of T lymphocytes infiltrating the tumor core or stroma has been linked to favorable prognosis in a large panel of malignancies.\textsuperscript{10,29} In line with this notion, a high density of CD3\(^+\) T cells in either primary or metastatic tumor biopsies has been attributed to independent prognostic value for improved PFS and overall survival (OS) in numerous cohorts of women with EOC (table 1).\textsuperscript{3,21,29–40} Importantly, such a positive prognostic impact is primarily associated with the expression of CD8\(^+\) T cell memory markers, markers of CD4\(^+\) T\(_{\text{H}1}\) polarization, and TIL localization to EOC islets rather than stromal areas.\textsuperscript{29,41,42} Moreover, although CD8\(^+\) T cell density appears to be increased in metastatic EOC samples compared with their primary counterparts,\textsuperscript{20,23} the abundance of CD8\(^+\) T cells in either compartment retains prognostic value.\textsuperscript{29,43}

A retrospective analysis of the immune landscape of more than 7000 EOC samples encompassing all major histological subtypes (HGSOC, LGSOC, MOC, EnOC, and OCCC) revealed that the strong positive prognostic impact of CD8\(^+\) TILs is limited to HGSOC, MOC, and EnOC, but not LGSOC and OCCC.\textsuperscript{44} Intriguingly, HGSOC generally harbors the most dense immune infiltrate as compared with other EOC subtypes.\textsuperscript{44} These findings have largely been recapitulated by independent investigators.\textsuperscript{11} Of note, abundant CD8\(^+\) T cell infiltration was linked to favorable disease outcome, regardless of residual disease, therapeutic strategy, or germline BRCA1 mutations.\textsuperscript{44} Similar results were obtained in a meta-analysis encompassing the results of 10 previously published studies, ultimately including a total of 1815 patients encompassing all EOC histologies.\textsuperscript{28}

Although some studies have attributed a negative prognostic value to robust EOC infiltration by TILs expressing programmed cell death 1 (PDCD1, best known as PD-1) or cytotoxic T lymphocyte-associated protein 4 (CTLA4), potentially linked to PD-1- or CTLA-4-dependent T cell exhaustion,\textsuperscript{35} other studies have revealed a rather beneficial prognosis, possibly because an elevated number of PD-1\(^+\) cells correlates with abundant tumor infiltration by T cells altogether\textsuperscript{35} or because a subset of CD8\(^+\)PD-1\(^+\) T cells expressing integrin subunit alpha E (ITGAE, best known as CD103) retain functional competence in the ovarian TME.\textsuperscript{35} In support of this possibility, a subset of CD8\(^+\)CD103\(^+\) T cells that was preferentially localized at epithelial tumor regions and expressed cytotoxic molecules has been significantly correlated with improved disease outcome in HGSOC patients.\textsuperscript{33,46,47} Conversely, CD8\(^+\) cytotoxic T lymphocytes (CTLs) expressing the coinhibitory receptor hepatitis A virus cellular receptor 2 (best known as TIM-3) exhibit bona fide features of functional exhaustion, and their abundance has been associated with poor disease outcome, indicating that TIM-3 plays a prominent role in limiting immune responses.
against HGSOC (table 1). In line with this notion, recent studies have identified a key role for the coexpression of various coinhibitory receptors for T cell exhaustion/dysfunction. Specifically, IL-27 was shown to drive a transcription program that promotes the coexpression of PD-1 and TIM-3, as well as lymphocyte activating 3 (LAG3) and T cell immunoreceptor with Ig and ITIM domains (TIGIT). Taken together, these findings identify a potential interaction between TIM-3 and other coinhibitory receptors that may be relevant for the establishment of robust immunosuppression in EOCs. In line with this possibility, coblockade of TIM-3 and PD-1 has been linked to tumor regression and improved anticaner T cell responses in patients with advanced solid carcinomas. Importantly, this combination might also circumvent some of the toxic effects observed with CTLA-4 and PD-1 coinhibition, as the expression of TIM-3 (but not CTLA-4 and PD-1) is predominantly linked to terminally differentiated T cells producing interferon gamma (IFNG).

In summary, tumor infiltration by CD8+ CTLs, memory T cells and Treg cells is associated with prolonged PFS and OS, particularly in patients with HGSOC. Conversely, tumor infiltration by TIM-3+ cells stands out as a negative prognostic factor. The impact of T cells expressing other activation and exhaustion markers on EOC outcome remains to be precisely elucidated.

**TREG cells**

TREG cells are a heterogeneous population of CD4+ T lymphocytes that express the high-affinity IL-2 receptor chain IL-2 receptor subunit alpha (best known as CD25) and the transcription factor FOXP3. TREG cells are essential for maintaining tolerance and preventing autoimmunity. However, developing malignancies, including EOC, harness TREG cells to establish local immunosuppression through a variety of mechanisms: (1) direct lysis of immune effector cells; (2) inhibition of antigen-presenting cells (APCs); (3) secretion of...
| Histology      | Stage   | No of patients | Method     | Impact                  | Note                                                                 | Ref. |
|---------------|---------|----------------|------------|-------------------------|----------------------------------------------------------------------|------|
| **T lymphocytes** |         |                |            |                         |                                                                      |      |
| Primary lesion |         |                |            |                         |                                                                      |      |
| **CD3⁺ T cell** |         |                |            |                         |                                                                      |      |
| EOC           | III, IV | 174            | IHC, IF    | Beneficial              | High density of intratumoral TILs correlated with improved survival   | 40   |
| HGSOC         | All     | 199            | IHC        | Beneficial              | High density of CD3⁺ T cells correlated with improved disease outcome | 3    |
| **CD8⁺ T cell** |         |                |            |                         |                                                                      |      |
| EOC           | All     | 270            | IHC        | Beneficial              | High density of CD8⁺ T cells correlated with favorable disease outcome | 29   |
| EOC           | All     | 117            | IHC        | Beneficial              | High density of CD8⁺ T cells correlated with favorable prognosis      | 30   |
| EOC           | All     | 500            | IHC        | Beneficial              | High density of CD8⁺ T cells associated with low BRCA1 expression     | 41   |
| EOC           | All     | 1815           | Meta-analyses | Beneficial              | High density of CD3⁺ and CD8⁺ T cells correlated with improved disease outcome | 28   |
| EOC           | All     | 497            | IHC, IF    | Beneficial              | High density of CD103 'CD8⁺ T cells correlated with improved survival | 33   |
| EOC           | II, III, IV | 203     | IHC, RT-PCR | Beneficial              | High density of CD8⁺ T cells correlated with favorable disease outcome | 34   |
| EOC           | All     | 70             | IHC        | Beneficial              | CD8⁺ T cells negatively correlated with PD-L1 expression in tumor      | 35   |
| EOC           | All     | 199            | IHC        | Beneficial              | High density of CD8⁺ T cells correlated with improved disease outcome | 3    |
| HGSOC, EnOC, OCCC | All     | 135            | IHC        | Beneficial              | High density of CD103 'CD8⁺ T cells correlated with improved disease outcome | 22   |
| EOC           | All     | 7377           | IHC        | Beneficial              | High density of CD8⁺ T cells correlated with prolonged OS             | 44   |
| EOC           | All     | 210            | IHC        | Beneficial              | High density of intratumoral CD8⁺ CTLs correlated with favorable disease outcome | 37   |
| HGSOC         | III     | 100            | IHC        | Beneficial              | High density and clonal selection of TILs correlated with improved disease survival | 31   |
| HGSOC         | All     | 178            | IHC        | Beneficial              | CD8⁺ T cells were shown to abolish clinically relevant chemoresistance by altering glutathione and cystine metabolism in malignant cells | 32   |
| HGSOC         | All     | 147            | IHC        | Beneficial              | High density of CD8⁺ T cells correlated with improved disease outcome | 21   |
| HGSOC         | All     | 232            | IHC        | Beneficial              | High density of CD8⁺ T cells correlated with improved disease outcome | 38   |
| HGSOC         | All     | 283            | IHC        | Beneficial              | High density of CD8⁺ T cells correlated with favorable prognosis      | 39   |
| HGSOC         | All     | 80             | IF         | Detrimental             | High density of PD-1⁺TIM-3 'CD8⁺ T cells correlated with poor disease outcome | 45   |
| **CD45RO⁺ T cell** |         |                |            |                         |                                                                      |      |
| EOC           | All     | 270            | IHC        | Beneficial              | High density of CD45RO⁺ memory T cells correlated with increased disease specific survival | 29   |
| EOC           | All     | 33             | IHC        | Beneficial              | High density of CD45RO⁺ T cells correlated with higher survival rate | 42   |

Continued
| **Histology** | **Stage** | **No of patients** | **Method** | **Impact** | **Note** | **Ref.** |
|--------------|-----------|--------------------|------------|------------|----------|---------|
| T\textsubscript{REG} cell | EOC | All | 270 | IHC | Beneficial | High density of T\textsubscript{REG} cells correlated with favorable disease outcome | 29 |
| | EOC | All | 92 | IHC, FC | Detrimental | High density of CD8\textsuperscript{+} T\textsubscript{REG} cells, induced by TGF\textbeta{}1, correlated with poor disease outcome | 66 |
| | EOC | All | 232 | IHC | Detrimental | High density of T\textsubscript{REG} cells associated with advanced stage of disease and suboptimal debulking | 38 |
| | EOC | III, IV | 26 | IHC, FC | Detrimental | High density of ICOS\textsuperscript{+} T\textsubscript{REG} cells, dependent on ICOS-L stimulation by pDC, correlated with poor disease outcome | 17 |
| | EOC | All | 103 | IF | Detrimental | High density of T\textsubscript{REG} cells, inducing the expression of B7-H4 on TAMs, correlated with poor disease outcome | 56 |
| | EOC | All | 70 | IF | Detrimental | High density of T\textsubscript{REG} cells in tumor and malignant ascites was associated with increased production of CCL22 by cancer cells and TAMs | 54 |
| | EOC | All | 869 | Meta-analyses | Detrimental | High density of T\textsubscript{REG} cells correlated with poor disease outcome | 55 |
| | EOC | All | 210 | IHC | Detrimental | High density of T\textsubscript{REG} cells in lymphoid aggregates correlated with reduced survival time | 37 |
| HGSOC | All | 199 | IHC | Beneficial | High density of T\textsubscript{REG} cells correlated with improved disease outcome | 3 |
| HGSOC, MOC, Other | All | 99 | IHC, RT-PCR | Detrimental | High density of T\textsubscript{REG} cells correlated with poor OS and PFS | 53 |
| HGSOC, MOC, OCCC | All | 25 | FC, RNAseq, Cytof | Detrimental | High density of T\textsubscript{REG} cells, suppressing CD8\textsuperscript{+} T cell proliferation, correlated with poor disease outcome | 62 |
| CD8/T\textsubscript{REG} cell | EOC | All | 270 | IHC | Beneficial | High ratio of CD8\textsuperscript{+} T cells/T\textsubscript{REG} cells correlated with improved disease outcome | 29 |
| | EOC | All | 117 | IHC | Beneficial | High CD8\textsuperscript{+} T cells/T\textsubscript{REG} cells ratio correlated with favorable prognosis | 30 |
| | EOC | All | 400 | IHC, IF | Beneficial | High CD8\textsuperscript{+} T cells/T\textsubscript{REG} cells ratio correlated with favorable prognosis | 57 |
| T\textsubscript{REG}/T\textsubscript{TH17} cell | EOC | III, IV | 124 | IF | Detrimental | High T\textsubscript{REG} cells/T\textsubscript{TH17} cells ratio, derived by TAMs, associated with disease progression and metastasis | 60 |

**Metastatic lesion**

| **CD8\textsuperscript{+} T cell** | EOC | III, IV | 147 | IHC | Beneficial | High density of CD8\textsuperscript{+} CTLs in omental metastasis correlated with improved disease specific survival | 29 |
| HGSOC | III, IV | 80 | IHC | None | High density of CD8\textsuperscript{+} T cells in peritoneal metastasis were not shown to associate with disease outcome | 20 |
| **CD45RO\textsuperscript{+} cell** | EOC | III, IV | 147 | IHC | Beneficial | High density of CD45RO\textsuperscript{+} T cells in omental metastasis correlated with improved disease specific survival | 29 |
| HGSOC | III, IV | 77 | FC | Beneficial | High density of CD45RA\textsuperscript{+}CCR7\textsuperscript{+} CD8\textsuperscript{+} T cells in peritoneal ascites correlated with improved RFS | 43 |
| **T\textsubscript{REG} cell** | EOC | III, IV | 147 | IHC | Detrimental | High density of T\textsubscript{REG} cells in omental ascites, mediated by CCL22 produced by cancer cells and TAMs, correlated with poor disease outcome | 29 |
| Table 1 | Contained |
|---------|-----------|
| **Histology** | **Stage** | **No of patients** | **Method** | **Impact** | **Note** | **Ref.** |
| **CD8/Treg** | EOC | III, IV | 147 | IHC | Detrimental | High CD8^+ T cells/Treg cells ratio in omental metastasis correlated with poor disease specific survival | 29 |
| **DCs** | | | | | | |
| **Primary lesion** | | | | | | |
| mDC | *EOC* | All | 33 | IHC | Beneficial | High density of CD1a^+ DCs correlated with improved OS | 42 |
| | n.a. | n.a. | n.a. | FC, IHC | Beneficial | High level of CXCL17 correlated with increased density of B7-H4^+ DCs and favorable disease outcome | 74 |
| | n.a. | n.a. | n.a. | FC, IHC | Beneficial | High density of CD103^+ DCs, as potent stimulators of CTLs, correlated with favorable disease outcome | 72 |
| HGSOC | All | 147 | IHC | Beneficial | High density of mature DC-LAMP^+ DCs correlated with increased frequency of CTLs and improved disease outcome | 21 |
| pDC | n.a. | All | 44 | FC | Detrimental | High density of CD4^+CD123^+BDCA2^+ pDC correlated with poor disease outcome | 77 |
| | EOC | All | 60 | IHC, FC | Detrimental | High expression of IDO correlated with reduced density of CD68^+ T cells, tumor progression and poor disease outcome | 78 |
| | n.a. | n.a. | n.a. | IHC, FC | Detrimental | SDF-1 was shown to induce chemotaxis and protection of pDCs from TAM-mediated apoptosis | 79 |
| EOC | III, IV | 26 | IHC, FC | Detrimental | High density of HLA-DR^+CD123^+ pDCs in malignant ascites correlated with poor disease outcome | 17 |
| **Metastatic lesion** | | | | | | |
| mDC | HGSOC | III, IV | 80 | IHC | Beneficial | High density of mature DC-LAMP^+ DCs in peritoneal metastasis correlated with improved disease outcome | 20 |
| pDC | n.a. | All | 44 | FC | Detrimental | High density of CD4^+CD123^+BDCA2^+ pDCs in malignant ascites correlated with poor disease outcome | 77 |
| **TLSs and B cells** | | | | | | |
| **Primary lesion** | | | | | | |
| B cell | *EOC* | All | 135 | IHC | Beneficial | High density of CD20^+ B cells correlated with improved disease outcome | 36 |
| | EOC | All | 266 | RNAseq | Beneficial | High BCR segments correlated with improved prognosis | 82 |
| | EOC | All | 154 | IHC | Detrimental | High density of CD138^+ plasma cells correlated with poor disease outcome | 85 |
| HGSOC, EnOC | All | 224 | RNAseq | Beneficial | High expression of CD38 correlated with favorable prognosis | 84 |
| HGSOC | All | 194 | IHC | Beneficial | High density of CD27 CD20^+ memory B cells correlated with cytolytic immune response and favorable prognosis | 81 |
| HGSOC | All | 147 | IHC | Beneficial | High density of CD20^+ B cells correlated with CTIs response and improved RFS and OS | 21 |
| HGSOC | All | 199 | IHC | Beneficial | High density of CD20^+ B cells correlated with favorable disease outcome | 3 |

Continued
immunosuppressive cytokines, such as IL-10 and transforming growth factor beta 1 (TGFβ1); and (4) depletion of growth factors and nutrients.52 While most circulating TREG cells stably express FOXP3 as a gene imprinted during thymic development, a tumor-infiltrating subset of TREG cells appears to retain some degree of plasticity and transdifferentiate towards a phenotype with limited immunosuppressive functions and the capacity to secrete IFNG and IL-17 under inflammatory conditions.51 52 Similarly, a subset of tumor-infiltrating TREG cells with a polarized CD4+ T cell can transdifferentiate into FOXP3+ TREG cells in response to TGFβ1.51

The majority of studies have shown that a high prevalence of TREG cells within TILs is associated with poor outcome in patients with all EOC histologies, especially when overall CTL infiltration is limited (table 1).17 30 37 38 35–36 Similar results were obtained by a meta-analysis of 869 patients encompassing all EOC histologies from four previous studies.55 Conversely, a positive prognostic value has been attributed to tumor-infiltrating TREG cells in a cohort of 270 HGSOC patients, most likely reflecting abundant TIL infiltration altogether.29 These findings suggest that the ratio of CTLs and TREG cells may constitute a superior indicator of active immunity in the ovarian TME, as validated in a number of studies.29 30 57

Tumor-infiltration by TREG cells is influenced by a variety of mechanisms, including multiple pathways driven by TAMs.58 For instance, C-C motif chemokine ligand 22 (CCL22), produced by malignant cells and TAMs, recruits TREG cells through a C-C motif chemokine receptor 4 (CCR4)-dependent mechanism.59 Moreover, miRNAs contained in TAM-derived exosomes appear to promote the interaction of TREG cells with CTLs, resulting in an increased TREG/TIL17 cell ratio and disease progression.60 Conversely, TREG cells promote expression of the immunosuppressive molecule V-set domain containing T cell activation inhibitor 1 (VTCN1, best known as PD-L1) on various APCs, including TAMs.56 Of note, hypoxia-induced upregulation of CCL28 also promotes the recruitment of TREG cells to the ovarian TME through a mechanism that involves CCR10 and ultimately leads to IL-10 production in support of disease progression.61 TREG cells isolated from HGSOCs express various receptors associated with TCR engagement, including the coinhibitory receptor PD-1 and the coactivating receptors inducible T cell costimulator and tumor necrosis factor receptor superfamily member 9 (TNFRSF9, best known as 4-1BB).62 Moreover, compared with TREG cells from other carcinomas, TREG cells from EOCs exhibit a highly activated state and increased immunosuppressive capacity, as documented in numerous studies on various histological subtypes of EOC.62

Thus, the abundance of TREG cells in primary EOC is commonly associated with poor disease outcome and metastatic progression. Conversely, the impact of TREG cell infiltration in metastatic EOCs remains relatively unknown.

**Table 1**

| Histology | Stage | No of patients | Method | Impact | Note | Ref. |
|-----------|-------|----------------|--------|--------|------|------|
| HGSOC     | All   | 155            | IHC    | Beneficial | High density of CD20+CD38+/CD138+/CD79a+ plasma cells correlated with CTLs response and improved disease outcome | 83 |
| TLS       | HGSOC | All             | 147    | None   | The presence of TLSs was not associated with disease outcome | 21 |
| TLS       | HGSOC | All             | 155    | Beneficial | TLSs were shown to facilitate the development of antitumor immunity associated with favorable disease outcome | 83 |

**Metastatic lesion**

| B cell | HGSOC | III, IV | 80 | IHC | None | High density of CD20+ B cells in peritoneal metastasis was not associated with disease outcome | 20 |
|-----------------|-------|---------|----|-----|------|---------------------------------------------------------------------|-----|
| HGSOC           | III, IV | 41      | IHC| Beneficial | High density of memory 20+ B cells in omental metastasis correlated with cytolytic immune response and favorable disease outcome | 89 |

*Encompassing all EOC histological subtypes.

**Dendritic cells**

Conventional DCs (cDCs) are commonly viewed as superior APCs, largely reflecting their capacity to efficiently process extracellular antigens and present them on MHC-II and MHC-I molecules to naïve CD4+ and CD8+ T cells, respectively, in the context of the abundant secretion of pro-inflammatory cytokines.63 Based on functional and phenotypic features, cDCs can be subdivided into at...
least two main subsets: type I (cDC1s) and type II cDCs (cDC2s),
classified as CD11c<sub>low</sub>HLA-DR<sup>DEC205</sup>XCR1<sup>+</sup>, and
CD11c<sup>+</sub>HLA-DR<sup>CD11b<sup>CD1a<sub>CD14</sub><sup>+</sup></sup></sup>, respectively.33 cDCs are not only highly proficient at
cross-priming tumor-targeting CD8<sup>+</sup> CTLs in tumor draining
lymph nodes but can also recruit T cells to the TME and
provide them with proinflammatory cytokines.60 Unfortunately,
cDCs are very rare in the ovarian TME and exhibit features of immaturity, especially at early disease
stages, implying that they might contribute to tumor
progression.64 At least in part, this reflects the abun-
dance of immunosuppressive cytokines, including IL-10,
TGFβ1, and VEGFA,148<sup>66</sup> and other immunosuppressive
factors, including the PD-1 ligand CD274 (best known as
PD-L1).67<sup>68</sup> In line with this notion, PD-L1 blockade
enhances DC-mediated T-cell activation, correlating with
IL-10 downregulation and increased secretion of IL-2 and
IFNG.69

HGSOC infiltration by BAFT3-dependent CD103<sup>+</sup>
cDC1s correlates with the abundance of C-X-C motif
chemokine receptor 3 (CXCR3) ligands, including
C-X-C motif chemokine ligand 9 (CXCL9), CXCL10, and
CXCL11, which facilitate the recruitment of clinically
relevant effector T cells into the TME.43<sup>70</sup> CD103<sup>+</sup> cDC1s are also dependent on the transcription factor IFN regu-
latory factor 8 (IRF8) and zinc finger and BTB domain
containing 4,71 as well as the cytokines colony stimulating
factor 8 (CSF8), CXCL11, which facilitate the recruitment of clinically
relevant effector T cells into the TME.43<sup>70</sup> CD103<sup>+</sup> cDC1s are also dependent on the transcription factor IFN regu-
latory factor 8 (IRF8) and zinc finger and BTB domain
containing 4,71 as well as the cytokines colony stimulating
factor 2 (CSF2, best known as GM-CSF) and FMS-related
receptor tyrosine kinase 3 ligand, which are associated with
favorable clinical outcome in ovarian carcinoma.72 Similarly, the abundance of mature DCs expressing lysosomal-
associated membrane protein 3 (LAMP3, best known as
DC-LAMP) has been associated with improved prognosis
in patients with various malignancies, including primary
and metastatic HGSOC.21 Of note, the majority of mature
DC-LAMP<sup>+</sup> DCs are localized to the tumor stroma and are
associated with tertiary lymphoid structures (TLSs)
rather than in direct contact with malignant cell nests.73 Nonetheless, an elevated density of mature DCs in the
ovarian microenvironment correlates with biomarkers of
T<sub>H</sub>1 polarization and cytotoxic activity, both of which are
involved in antiviral immune responses, reflecting their
capacity to produce elevated amounts of type I IFN on
activation.75 High levels of pDCs in the ovarian micro-
environment are generally associated with immuno-
suppression and poor prognosis, as comprehensively
documented in patients with various EOC histological
subtypes (table 1).17<sup>18</sup> 76–79 IL-10 and CXCL12 are the
primary factors responsible for EOC infiltration by
CXCR4-expressing pDC precursors, culminating in the
accumulation of pDCs expressing the immunosuppressive
enzyme IDO1.78<sup>79</sup> Consistent with this, a high density of
pDCs in the EOC environment is associated with impaired
TIL proliferation, decreased effector functions as well as

B cells and TLSs
Tumor infiltration by B cells is robustly associated with
improved survival in patients with EOC, especially
HGSOC (table 1).3<sup>21</sup> 36<sup>81–85</sup> Nevertheless, accumulating
findings suggest a positive impact of B cells also in other
histological EOC subtypes, including MOC, EnOC, and
OCCC.36<sup>84</sup> Although B cells primarily reside in the tumor
stroma in the context of TLSs, they can also be found
within tumor cell nests.86 B cells at all stages of differenti-
ation have been detected in EOC, including IgD<sup>CD38</sup>−/−
naive B cells, IgD<sup>CD38</sup><sup>+</sup> pregerminal and IgD<sup>CD38</sup>−
germinal B cells; IgD<sup>CD38</sup>−/− memory B cells as well as
plasma cells (PCs) with an IgD<sup>CD38</sup><sup>+</sup> phenotype.87

Interestingly, in the ovarian setting, TLSs are frequently
surrounded by dense infiltrates of mature PCs.83<sup>85</sup> PCs are
generally associated with a high density of CD8<sup>+</sup>
CD4<sup>+</sup> T cells, as well as CD20<sup>+</sup> B cells, which stands out
as an immunological configuration compatible with the
induction of clinically relevant tumor-targeting immunity.83
CD20<sup>+</sup> B cells are found in more than 40% of
HGSOCs, and their abundance also correlates with
tumor infiltration by CD4<sup>+</sup> and CD8<sup>+</sup> T cells, as well as with
the abundance of transcripts encoding various T cell
markers, such as TIA1 cytotoxic granule associated
RNA binding protein (TIA1), granzyme B (GZMB) and
FOXp3.32<sup>1</sup> Importantly, abundant EOC infiltration by both
CD8<sup>+</sup> CTLs and CD20<sup>+</sup> B cells is associated with a
more favorable disease outcome than infiltration by either cell
population alone, suggesting the existence of cooperative
interactions between CD8<sup>+</sup> CTLs and CD20<sup>+</sup> B cells in the
ovarian microenvironment.21<sup>84</sup> In line with this notion, the
majority of EOC-infiltrating CD20<sup>+</sup> B cells express
high levels of costimulatory molecules, including CD80
and CD86, as well as MHC Class I and Class II molecules,
as they display a CD27 memory phenotype linked to markers of somatic hypermutation, oligoclonality and IgG class switching. 88

As recently shown by us and others, both omental and peritoneal HGSOC metastases are highly infiltrated by CD20+ B cells with a memory phenotype. 90 23 89 As in primary EOCs, transcript levels of CD20 correlate with markers of cytotoxic responses, suggesting that B cells infiltrating metastatic EOC promote anticancer immune responses, a notion that has been mechanistically validated on B-cell depletion in syngeneic mouse models of peritoneal metastasis. 90 Although the density of CD20+ B cells is significantly increased in peritoneal metastases compared with primary EOC lesions, 23 the abundance of metastasis-infiltrating CD20+ B cells is not associated with disease outcome (table 1). 20

Taken together, these observations suggest that TLSs represent key sites for the induction and maintenance of clinically relevant EOC-targeting immunity and that B cells mediate a central function in this context. An improved understanding of the biology of tumor-infiltrating B cells is highly anticipated to harness this lymphocyte subset for therapeutic purposes.

**Tumor-associated macrophages**

TAMs, which constitute the largest fraction of the myeloid infiltrate in the majority of solid malignancies, including all EOCs, 90 can be found within tumor cell nests, at the tumor invasive margin and in the stroma. A high degree of TAM heterogeneity has been observed not only across different histological subtypes of EOC, with HGSOCs and MOCs being the EOCs most abundantly infiltrated by TAMs, but also in women with the same EOC subtype and even different EOC lesions in the same patient. 90 91 Moreover, TAMs display a high degree of functional plasticity and can rapidly adapt to changing microenvironmental conditions to acquire different phenotypic, metabolic, and functional profiles. 92 In particular, exposure of infiltrating monocytes and macrophages to cytokines, such as IL-4, IL-5, IL-10, IL-13, CCL2, TGFβ1, and CSF1 (best known as M-CSF), as well as to prostaglandin E2 (PGE2), which is abundantly produced by dying cancer cells, promotes the acquisition of anti-inflammatory and protumoral (so-called M2-like) properties. 93

In ovarian carcinoma, M2-like TAMs robustly promote neo-angiogenesis and disease progression in the context of largely immunosuppressive rewiring of the TME. 94 In line with this notion, high levels of CD206,CD163+CD204+ M2-like TAMs within primary and metastatic EOCs of all histologies are generally associated with reduced sensitivity to treatment and poor prognosis (table 2). 65 94-100 Conversely, M1-like TAMs, defined as CD68+CD86+HLA-DR+iNOS+ cells, constitute a good prognostic factor in women with EOC, largely reflecting their ability to promote robust inflammatory responses that limit disease progression, although their presence is significantly decreased in the TME of patients with advanced EOC (table 2). 91 98 101 102

The immunosuppressive functions of M2-like TAMs involve a variety of global anti-inflammatory cytokines (eg, IL-10 and TGFβ1) and chemokines (eg, CCL17, CCL18, CCL22) that facilitate the following functions: (1) inhibiting antigen presentation to T cells, (2) subverting DC maturation, (3) blocking CTL effector functions, and (4) driving the recruitment of Treg cells. 103 M2-like TAMs in the ovarian TME also limit immune effector functions by producing exosomes. 60 Specifically, TAM-derived exosomes contain high amounts of proteins, as well as DNA, mRNA and miRNA molecules, which together suppress T cell activity and promote an imbalance between Treg cells and Th17 cells by directly targeting signal transducer and activator of transcription 3 (STAT3) in CD4+ T cells. 60

Multiple studies have identified a crucial role for TAMs, especially CD163+TIM-4+ omental TAMs, in the metastatic dissemination of ovarian cancer cells to the peritoneal cavity. 19 Indeed, the specific depletion of this TAM population prevents the development of metastatic disease in mouse models of ovarian cancer, and the molecular circuitries that underlie these functions may represent a novel therapeutic target in the ovarian setting. 19 Moreover, TAMs are important for the formation of spheroids during transcoelomic EOC metastasis. In particular, TAMs can produce large amounts of epidermal growth factor (EGF) to activate EGF receptor (EGFR) and VEGFC signaling in surrounding cells, ultimately leading to upregulation of multiple integrins and intercellular adhesion molecule 1 (ICAM1) and hence promoting cancer cell proliferation, migration, adhesion, spheroid formation and implantation into the peritoneal cavity. 94 In line with this notion, EGFR-blocking and ICAM1-blocking strategies inhibit spheroid formation and metastatic disease progression in mouse models of EOC, 94 standing out as potential targets for the development of novel approaches to the management of EOC patients.

Finally, TAMs support tumor progression by increasing the availability of selected nutrients in the primary, and even more so metastatic, ovarian TME. Specific TAM subsets can indeed accumulate lipids in support of their immunomodulatory properties, ultimately leading to deregulation of multiple factors involved in lipid metabolism, including the lipid chaperones fatty acid binding protein 4 (FABP4) and FABP5. 104 In advanced EOC, TAMs preferentially express FABP4, which supports tumor progression by favoring IL-6-driven STAT3 signaling. 105 FABP4 also plays a key role in the interaction between ovarian cancer cells and adipocytes. 104 In line with these observations, FABP4 deficiency impairs metastatic tumor growth in mouse models of EOC. 106 Intriguingly, EOC cells actively promote cholesterol efflux by TAMs, culminating in depletion of lipid rafts and increased IL-4 signaling. 107 Thus, genetic deletion of the ABC transporters that mediate cholesterol efflux limits EOC progression in mice. 107

Altogether, these findings indicate that EOCs harness macrophage polarization to an M2-like phenotype as a mean to establish immunosuppression in support of local and distant disease dissemination. The therapeutic
| Table 2  Prognostic relevance of tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), natural killer (NK) cells and cancer associated fibroblasts (CAFs) in primary and metastatic ovarian carcinoma |
|-------------------------------------|--------|-------|-----------------|-------|-----------------|-------|
| **Histology** | **Stage** | **No of patients** | **Method** | **Impact** | **Note** | **Ref.** |
| **Primary lesion** | | | | | |
| M1-like TAM | EOC* | III, IV | 140 | FC | Beneficial | High density of M1-like TAMs correlated with favorable disease outcome |
| | EOC | III, IV | 102 | IHC, IF | Beneficial | High M1/M2-like TAMs ratio correlated with improved disease outcome |
| | EOC | All | 112 | IHC, IF | Beneficial | High M1/M2-like TAMs ratio correlated with improved disease outcome |
| M2-like TAM | EOC | All | 794 | Meta-analyses | Detrimental | High density of M2-like TAMs correlated with poor disease outcome |
| | EOC | III, IV | 110 | IHC | Detrimental | High density of CD163+ TAMs and high CD163/CD68+ cells ratio correlated with poor PFS and OS |
| | EOC | III, IV | 102 | IHC, IF | Detrimental | High expression of Mucin-2 correlated with low M1/M2-like TAMs ratio and poor disease outcome |
| | EOC | III | 128 | IHC | Detrimental | High density of EGF-secreting M2-like TAMs correlated with poor disease outcome |
| | EOC | All | 124 | IHC, IF | Detrimental | High density of TAMs-derived exosomes correlated with high Treg/T_{h17} ratio and poor disease outcome |
| | n.a. | All | n.a. | IHC | Detrimental | Low expression of tumor cell derived MIF correlated with increased apoptosis of malignant cells and favorable disease outcome |
| HGSOC | All | 30 | FC | Detrimental | High density of M2-like TAMs correlated with poor RFS and OS |
| HGSOC | All | 199 | IHC, IF | Detrimental | High density of CD206+CD68+ cells correlated with poor disease outcome |
| **Metastatic lesion** | | | | | |
| M1-like TAM | EOC | III, IV | 140 | FC | Beneficial | High density of M1-like TAMs in malignant ascites correlated with favorable disease outcome |
| M2-like TAM | EOC | III | 128 | IHC | Detrimental | High density of EGF-secreting M2-like TAMs correlated with poor disease outcome |
| HGSOC | III, IV | 50 | IF | Detrimental | High density of CD68+CD163+ M2-like TAMs in peritoneal metastasis correlated with poor RFS and OS |
| HGSOC | All | 30 | FC | Detrimental | High density of M2-like TAMs in malignant ascites correlated with poor RFS and OS |

Continued
| Table 2 | Continued |
|---|---|---|---|---|---|---|---|---|---|
| Histology | Stage | No of patients | Method | Impact | Note | Ref. |
| **MDSCs** | | | | | | |
| Primary lesion | | | | | | |
| MDSC | *EOC* | All | 32 | FC | Detrimental | High density of M-MDSCs correlated with poor disease outcome | 110 |
| | HGSOC, EnOC, MOC | All | 29 | FC | None | High density of PD-L1⁺ MDSCs was not associated with disease outcome | 117 |
| | HGSOC | III, IV | 79 | IF, FC | Detrimental | High expression of AMPKα1 associated with immunosuppressive activity of MDSCs | 124 |
| | HGSOC | III, IV | 56 | Microarray IHC | Detrimental | High VEGF levels correlated with MDSC migration and poor prognosis | 14 |
| | HGSOC | All | 140 | IHC | Detrimental | High density of MDSCs correlated with inhibited T cell activation, cancer metastasis and poor disease outcome | 123 |
| | n.a. | All | 60 | IHC | Detrimental | High density of MDSCs associated with stemness of cancer cells induced by CSF2/p-STAT3 signaling pathway | 114 |
| | n.a. | All | 340 | IHC, IF | Detrimental | High levels of PGE2 produced by MDSCs correlated with increased PD-L1 expression and stem cell-like properties of cancer cells | 116 |
| | n.a. | All | 52 | FC | Detrimental | Metformin derived inhibition of CD73/CD39 expression in MDSCs correlated with decreased immunosuppression and favorable disease outcome | 118 |
| | n.a. | III, IV | n.a. | RT-PCR, ELISA | Detrimental | High levels of CXCL1/2 correlated with Snail expression, MDSC infiltration and poor disease outcome | 115 |
| Metastatic lesion | | | | | | |
| MDSC | EOC | III, IV | n.a. | ELISA, FC | Detrimental | High CXCL12 levels correlated with accumulation of MDSCs in malignant ascites and poor disease outcome | 113 |
| | EOC | All | 29 | FC | Detrimental | High density of M-MDSCs in peritoneal fluid correlated with poor disease outcome | 110 |
| | EOC | All | 31 | ELISA | Detrimental | High IL-6 and IL-10 levels correlated with accumulation of CD14⁺HLA-DR⁺MDSCs in malignant ascites and poor disease outcome | 111 |
| | EOC | III, IV | 13 | FC ELISA | Detrimental | High density of MDSCs in malignant ascites correlated with increased level of NO and enhance development of T₁₇ cells from CD4⁺ precursors | 119 |
| Histology | Stage | No of patients | Method       | Impact   | Note                                                                                                                                 | Ref. |
|-----------|-------|----------------|--------------|----------|---------------------------------------------------------------------------------------------------------------------------------------|-----|
| EOC       | III, IV | 15             | FC, ELISA    | Detrimental | High density of MDSCs associated with overexpression of IDO, iNOS/NOS2, IL-10 in malignant ascites and suppression of T<sub>1</sub> T-mediated antitumor immune response | 120 |
| EOC       | III, IV | 22             | RT-PCR       | Detrimental | High density of MDSC in malignant ascites associated with PGE2-derived DNMT3A upregulation and immunosuppression                     | 112 |
| HGSOC, EnOC, MOC | All   | 26             | FC           | None      | High density of MDSCs in malignant ascites was not associated with disease outcome                                                   | 117 |
| **NK cells**                                        |                                               |              |           |                                                                                                                                      |     |
| **Primary lesion**                                   |                                               |              |           |                                                                                                                                      |     |
| NK cells *EOC*                                       | All                                           | 497          | IHC, IF    | Beneficial | High density of CD103<sup>+</sup> NK cells correlated with favorable disease outcome                                                   | 33  |
| HGSOC     | All                                           | 283          | IHC         | Beneficial | High density of CD57<sup>+</sup> NK cells correlated with favorable prognosis                                                       | 39  |
| HGSOC     | All                                           | 81           | IHC         | None       | High density of mature DC-LAMP<sup>+</sup> DCs correlated with higher frequency of cytotoxic NKP46<sup>+</sup> NK cells            | 21  |
| Serous, MOC, EnOC                                   | All                                           | 38           | IHC, IF    | Beneficial | High expression of MIF correlated with impaired NK cells cytotoxicity and poor prognosis                                               | 13  |
| **Metastatic lesion**                                |                                               |              |           |                                                                                                                                      |     |
| NK cells HGSOC                                      | III, IV                                       | 80           | IHC        | None        | High density of NKP46<sup>+</sup> NK cells in peritoneal metastasis did not correlate with disease outcome                             | 20  |
| HGSOC     | III, IV                                       | 20           | FC          | Beneficial | High density of CD56<sup>+</sup> NK cells in peritoneal ascites correlated with improved OS and RFS                                 | 127 |
| Papillary serous                                    | III                                           | 50           | FC          | Detrimental | Low expression of NKP30 correlated with impaired cytotoxicity and poor disease outcome                                              | 131 |
| n.a.      | III, IV                                       | n.a.         | FC          | Beneficial | High density of NK cells correlated with increased recruitment of iDCs and effector CD8<sup>+</sup> T cells                        | 133 |
| **CAFs**                                            |                                               |              |           |                                                                                                                                      |     |
| **Primary lesion**                                   |                                               |              |           |                                                                                                                                      |     |
| CAF       *EOC*                                      | All                                           | 527          | IHC        | Detrimental | High levels of IL-1β and low expression of p53 in CAFs correlated with poor disease outcome                                         | 142 |

Table 2 Continued

Continued
potential of TAM-targeting or TAM-repolarizing agents, such as CSF 1 receptor (CSF1R) inhibitors in patients with EOC, however, remains to be elucidated.

**Myeloid-derived suppressor cells**

MDSCs are a heterogeneous population of relatively immature myeloid cells that differ in morphology and function from terminally differentiated myeloid cells, such as DCs, macrophages and neutrophils. They are two major groups of MDSCs in humans, namely, granulocytic/polymorphonuclear MDSCs (PMN-MDSCs), which generally display a CD11b+CD33+CD14−CD15+ surface phenotype, and monocyctic MDSCs (M-MDSCs), which are most often CD11b+CD33+CD14−CD15−. An increased number of circulating or tumor-infiltrating MDSCs has been detected in patients with various malignancies, including women with primary and metastatic cancers.

---

### Table 2

| Histology | Stage | No of Patients | Method | Impact | Note | Ref. |
|-----------|-------|----------------|--------|--------|------|------|
| EOC       | II, III, IV | 255 | IHC | Detrimental | High levels of IL-6 in CAFs correlated with paclitaxel chemoresistance and poor disease outcome | 224 |
| HGSOC     | n.a. | n.a. | IHC | Detrimental | High expression of LPP correlate with chemoresistance and poor disease outcome | 149 |
| HGSOC     | III, IV | 15 | Microarray | Detrimental | High expression of versican (VCAN) in CAFs mediated by TGFβ1 promote the motility and invasion of tumor cells | 146 |
| HGSOC     | III, IV | 144 | RT-PCR | Detrimental | High levels of HOXA9 stimulate CAFs and correlated with poor disease outcome | 153 |
| n.a.      | III, IV | 66 | IHC | Detrimental | High expression of FAB correlated with poor disease outcome | 138 |
| n.a.      | n.a. | n.a. | ELISA | Detrimental | High expression of FGF1 correlated with disease progression and poor outcome | 139 |
| n.a.      | n.a. | n.a. | IF | Detrimental | High levels of CAFs associated with chemoresistance and poor disease outcome | 150 |

### Metastatic lesion

| CAF | HGSOC | III, IV | n.a. | miRNA, gene array analyses | Detrimental | MicroRNAs reprogram normal fibroblasts into CAFs associated with poor disease outcome | 143 |
| HGSOC | III, IV | n.a. | In vitro testing | Detrimental | Chemokines and cytokines produced by CAFs are required for stimulation of glycogen mobilization and cancer metastasis | 144 |
| HGSOC | III, IV | n.a. | ELISA | Detrimental | High level of TGFβ1 in CAF exosomes correlated with poor disease outcome | 154 |

*Encompassing all EOC histological subtypes*
Nevertheless, association between histological subtypes of EOC and MDSC abundance has never been investigated. Various tumor-derived cytokines (e.g., IL-6, IL-10, IL-18, TNF, and VEGFA), growth factors (e.g., M-CSF, GM-CSF) and other mitogens (e.g., PGE2) promote the formation of MDSCs from myeloid progenitors in the bone marrow.111–113 This largely reflects the activation of signaling transduction cascades culminating with STAT3 signaling, which also promotes MDSC immunosuppression by downregulating IRF8 while upregulating CCAAT enhancer binding protein beta.114 Conversely, the accumulation of MDSCs within neoplastic lesions is driven by a variety of cytokines and chemokines, including CXCL1, CXCL8, CXCL12, CCL1, CCL2, CCL3, CCL5 and CCL7, which primarily operate via CCR4 and CCR5.113,115

Accumulating preclinical and clinical evidence indicates that PMN-MDSCs and M-MDSCs suppress both innate and adaptive immune responses driven by ovarian cancer cells.116–120 While the majority of such studies focused on HGSCs, data from a limited number of patients with MOC and EnOC also support the protumoral role of MDCs.110 Of note, PMN-MDSCs preferentially use reactive oxygen species, peroxynitrite, ARG1 and PGE2 to a variety of cytokines and chemokines, including CXCL1, which mediate immune suppression.112,119 Conversely, M-MDSCs predominantly harness nitric oxide, immunosuppressive cytokine such as IL-10 and TGFβ1, and membrane-bound molecules, such as PD-L1 to impair CTL and NK cell functions.121 MDSCs also drive tumor progression by favoring epithelial-to-mesenchymal transition (EMT), invasiveness and metastatic dissemination in malignant cells and by promoting neoangiogenesis.114,116 Recent data suggest that MDSCs are also involved in the establishment of the premetastatic niche.122 Consistent with these findings, elevated numbers of circulating or intratumoral MDSCs correlate with poor disease outcome in women with various EOC subtypes (table 2).14,110,112,113,125,124

Altogether, these observations suggest that both M-MDSCs and PMN-MDSCs establish immunosuppression and support metastatic dissemination in EOC. Thus, targeting MDSCs stands out as a promising approach to promote EOC-directed immune responses. Potential approaches to this objective include (1) blocking the formation of MDSCs in the bone marrow, (2) impeding MDSC recruitment to neoplastic lesions, and/or (3) reprogramming MDSCs to terminally differentiate and lose their immunosuppressive potential.

**NK cells**

NK cells are a subset of innate lymphoid cells that play a central role in defending the organism from viral infection, early malignant transformation and metastatic tumor dissemination.125,126 NK cell effector functions encompass potent cytotoxicity against target cells, as well as the secretion of immunomodulatory cytokines that orchestrate innate and adaptive immune responses.126 Such functions do not involve the recognition of specific antigens, as they do in the case of CTLs, but are controlled by the balance between inhibitory and stimulatory signals that are conveyed to NK cells on interaction with potential targets.125

Results on EOC infiltration by NK cells are rather inconsistent, at least in part due to the use of rather heterogeneous markers for NK cell detection (table 2).15,20,21,33,39,127,129 Thus, high levels of NK cells in the TME of all EOC subtypes have been positively associated with improved prognosis when beta-1,3-glucuronyltransferase 1 (best known as CD57) and CD103 were used as phenotypic markers, although these molecules are also expressed by activated CD8+ T cells.33,39 In contrast, when NK cells were identified using natural cytotoxicity triggering receptor 1 (NCR1, best known as Nkp46), their abundance in primary and metastatic HGSC lesions did not correlate with clinical outcome,20,21 perhaps due to functional impairments imposed by local immunosuppression.129 Indeed, NK cell effector functions in peritoneal ascites are inhibited on MIF-driven downregulation of killer cell lectin-like receptor K1 (KLRL1, best known as NKG2D).13,130 Additionally, NK cell cytotoxicity in the TME of metastatic EOC is limited on the downregulation of NCR2 (best known as Nkp30), as induced by soluble and surface-exposed NK cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, best known as B7-H6).131 In line with these findings, increased B7-H6 expression has been associated with metastatic disease progression and poor clinical outcome in patients with various EOC histological subtypes.109

In addition to mediating direct cytotoxic effects against neoplastic cells, NK cells can also exert anticancer activity by engaging the adaptive arm of the immune system. Specifically, NK cells can recruit cDCs to the TME on secretion of CCL5, X-C motif chemokine ligand 1 (XCL1) and XCL2.132 Moreover, IL-18-primed NK cells can favor tumor infiltration through immature DCs via CCL3 and CCL4, a process that culminates in the secretion of CTL chemoattractants, including CXCR3 and CCR5 ligands.133 Altogether, these observations indicate that NK cells dynamically interact with malignant and immune components of the ovarian TME most often in support of anticancer immunity. However, available data fail to elucidate a robust prognostic value for EOC infiltration by NK cells, potentially linked to an elevated degree of methodological heterogeneity and/or to the functional impairment of EOC-infiltrating NK cells downstream of local immunosuppression. Efforts aimed at homogenizing the quantification of EOC-infiltrating NK cells and obtaining further insights into their functional rewiring on tumor infiltration are urgently needed to clarify the therapeutic potential of NK cell-targeting agents in women with EOC.126

**Cancer-associated fibroblasts**

Cancer-associated fibroblasts (CAFs) are key components of the ovarian TME with diverse biological functions, including matrix remodeling as well as reciprocal interactions with TILs and cancer cells.134,135 Tissue-resident quiescent fibroblasts, which are predominant in the normal stroma, and mesenchymal stem cells transform
into CAFs on interaction with cancer cells.\(^{136\ 137}\) CAFs found in EOC lesions generally express actin alpha 1, skeletal muscle (ACTA1, best known as SMA), fibroblast activation protein alpha, S100 calcium binding protein A (S100A4, best known as FSP1) and fibroblast growth factor 1 (FGF1).\(^{138\ 139}\) However, due to the continuous reciprocal interactions between CAFs with cancer cells, the former tend to undergo dynamic changes that enable high degrees of phenotypical and functional heterogeneity.\(^{139\ 140}\) Indeed, neoplastic cells secrete various cytokines and soluble factors such as IL-6, IL-8, IL-1β, TGFβ1, platelet-derived growth factor, FGF and EGF to activate fibroblasts.\(^{141\ 142}\) Moreover, ovarian cancer cells reprogram fibroblasts to become CAFs via alterations in the levels of 3 miRNAs, namely downregulation of miR-214 and miR-31, coupled to upregulation of miR-155.\(^{143}\)

On reprogramming, CAFs promote tumor growth and invasion through increased secretion of multiple cytokines, chemokines and growth factors such as CCL5, IL-6, IL-8, TGFβ1, VEGFA among others.\(^{144-146}\) Moreover, CAFs promote EOC progression by favoring the EMT.\(^{141\ 147}\) angiogenesis,\(^{147}\) altered cancer metabolism\(^{144\ 148}\); chemoresistance,\(^{149\ 150\ 151}\) and immune modulation.\(^{151\ 152}\) However, an extensive description of all the mechanisms through which CAFs drive EOC progression goes largely beyond the scope of this review, and can be found elsewhere.\(^{134\ 135}\) Importantly, CAF abundance positively correlate with disease progression and poor disease outcome in women with primary\(^{138\ 139\ 142\ 150\ 153}\) and metastatic EOC\(^{143\ 144\ 154}\) (table 2).

In summary, CAFs may also constitute valuable target to limit immunosuppression in the TME of patients with EOC. So far, this strategy has been mostly been investigated in other tumors with a large CAF component, such as pancreatic carcinoma.\(^{134}\)

Cytokine and chemokine profile

Accumulating preclinical and clinical evidence indicates that the cytokine and chemokine milieu of EOC plays a key role in the establishment of local and systemic immune contexture (table 3).\(^{155\ 156}\) Thus, the intratumoral or circulating abundance of multiple cytokines and chemokines impacts disease outcome in patients with EOC. For instance, elevated IL-6 levels in the ovarian TME have been associated with disease progression, resistance to treatment and poor clinical outcome in patients with various EOC subtypes.\(^{156-159}\) At least in part, this reflects the ability of IL-6 to promote EOC cell invasion through the basal membrane, as well as to (1) mediate mitogenic effects linked to chemoresistance and (2) promote IL-10 secretion.\(^{160}\) Moreover, IL-6 reportedly activates protumorigenic signal transducers, including JAK1 (Janus kinase 1) and STAT3.\(^{161\ 162}\) In metastatic EOC, TAMs are the primary producers of IL-6, and their presence, as well as high bloodborne and peritoneal IL-6 levels, correlate with poor disease outcome.\(^{66\ 111\ 159\ 160}\) Similar findings have been obtained with IL-8, IL-10, VEGFA, TGFβ1 and TNF, all of which appear to condition the ovarian TME in favor of disease progression and escape from immunosurveillance (figure 2 and table 3).

The overall chemokine landscape of EOC is heterogeneous, with CCL2, CCL5, CXCL12 and CXCL16 being the most predominant molecules.\(^{153}\) Importantly, the high levels of CXCR6 and CXCL16 in serous papillary carcinoma tissues suggests an association with aggressive histological subtype as compared with EnOC.\(^{169}\) CCL2 is mostly produced by malignant cells and contributes to TAM accumulation.\(^{170}\) Conversely, while CCL4 and CCL5 expression is mostly associated with CTL recruitment,\(^{133\ 151}\) CXCL22 and CCL28 levels positively correlate with an increased abundance of T\(_{\text{REG}}\) cells (at least in primary EOCs).\(^{34\ 61\ 155}\) The expression of genes associated with T cell recruitment is restricted to the epithelial tumor component and preserved across metastatic sites, suggesting that T cells might easily home to metastatic lesions.\(^{155}\) However, the impact of some cytokines and chemokines on EOC progression and clinical outcome is controversial. For instance, although EOC-derived CXCL12 is associated with T cell recruitment,\(^{172}\) as are CXCL9 and CXCL10,\(^{173}\) it also drives tumor progression by activating the MAPK cascade in EOC cells.\(^{174}\) Consistent with this notion, high levels of CXCL12 or its receptor (CXCR3), as well as CXCL16, CXCR6 and CCL8, have been associated with metastatic dissemination to the peritoneum and ascites formation (table 3).\(^{169\ 173-175}\)

In summary, the net effect of cytokine and chemokine signaling on EOC progression depends on the balance between their ability to recruit and activate specific immune cell populations and their capacity to drive mitogenic signaling in EOC cells.

MODULATING THE OVARIAN TME

EOC was one of the first malignancies in which a positive association between TIL density and OS was identified.\(^{64}\) However, EOC-infiltrating lymphocytes are often suppressed and/or functionally exhausted by a variety of mechanisms, including (but not limited to) (1) abundant secretion of immunosuppressive cytokines, such as TGFβ1, IL-6 and IL-10, by EOC cells;\(^{65\ 66\ 156\ 163}\) (2) expression of metabolic immunosuppressors, such as IDO\(^{178}\); (3) robust tumor infiltration by immunosuppressive T\(_{\text{REG}}\) cells;\(^{58\ 46\ 54}\) M2-like TAMs and MDSCs;\(^{94\ 95\ 165}\); and (4) activation of coinhibitory receptors, such as PD-1 and TIM-3.\(^{45\ 176}\) In line with such multipronged immunosuppression, ICIs are not very effective in women with EOC.\(^{177}\)

Chemotherapy

Some anticancer agents, including conventional chemotherapeutics, targeted drugs and radiation therapy (RT), can be harnessed to stimulate anticancer immunity, as they can increase the antigenicity of malignant cells, boost their adjuvanticity or repolarize the TME in support of immunological disease control.\(^{178}\) At least in principle,
**Table 3** Pro-tumoral and anti-tumoral roles of cytokines and chemokines in primary and metastatic ovarian carcinoma

| Histology  | Stage     | No of patients | Method          | Impact     | Note                                                                 | Ref. |
|------------|-----------|----------------|-----------------|------------|----------------------------------------------------------------------|------|
| **Primary lesion** |           |                |                 |            |                                                                       |      |
| IL-6       | *EOC*     | All            | 94              | IHC        | Detrimental High IL-6 levels correlated with proliferation and invasivity of cancer cells | 159  |
|            | EOC       | All            | 221             | IHC        | Detrimental High IL-6 levels correlated with tumor growth, high frequency of TAMs infiltrate, angiogenesis and poor disease outcome | 157  |
|            | HGSOC     | III, IV        | 53              | IHC, IF    | Detrimental High IL-6 levels correlated with angiogenesis, increased infiltration of myeloid cells and poor disease outcome | 156  |
|            | n.a.      | n.a.           | 25              | IHC        | Detrimental High IL-6 levels correlated with disease progression       | 158  |
| IL-8       | HGSOC, MOC, EnOC | All       | 44              | RT-PCR, IHC | Detrimental High IL-8 levels correlated with malignant transformation and poor disease outcome | 164  |
| IL-10      | HGSOC     | III, IV        | 30              | ELISA      | Detrimental High IL-10 levels correlated with M2-like TAMs polarization and poor prognosis | 65   |
| TGFβ       | EOC       | All            | 92              | IHC, FC    | Detrimental High TGFβ1 levels associated with CD8+ Treg induction and poor prognosis | 66   |
|            | HGSOC, EnOC | All       | 25              | IHC, RT-PCR| Detrimental High TGFβ levels associated with cancer cells proliferation and poor disease outcome | 163  |
| VEGF       | HGSOC     | III, IV        | 56              | Microarray, IHC | Detrimental High VEGF levels correlated with MDSC migration and poor prognosis | 14   |
|            | HGSOC, MOC, EnOC | All       | 44              | RT-PCR, IHC| Detrimental High VEGF levels correlated with malignant transformation and poor prognosis | 164  |
| TNFα       | EOC       | III, IV        | 60              | FC, ELISA, RT-PCR | Detrimental High TNF levels correlated with myeloid cells recruitment and tumor progression | 165  |
|            | HGSOC     | III, IV        | 53              | IHC, IF    | Detrimental High TNF levels correlated with angiogenesis, increased infiltration of myeloid cells and poor disease outcome | 156  |
| IDO        | EOC       | All            | 60              | IHC        | Detrimental High IDO levels correlated with impaired OS and PFS        | 78   |
| CCL2       | HGSOC, MOC, EnOC | All       | 46              | ELISA      | Detrimental High CCL2 levels correlated with TAMs recruitment and poor disease outcome | 170  |
| CCL5       | n.a.      | All            | n.a.            | ELISA, RT-PCR | Beneficial High CCL5 levels associated with recruitment of effector CD8+ T cells and favorable disease outcome | 133  |

Continued
| **Histology** | **Stage** | **No of patients** | **Method** | **Impact** | **Note** | **Ref.** |
|--------------|-----------|--------------------|------------|------------|----------|---------|
| CCL18        | HGSOC, MOC| All                | 59         | RT-PCR, IHC| Detrimental | High CCL18 levels correlated with metastatic spread and poor disease outcome | 175 |
| CCL22        | EOC       | All                | 70         | ELISA      | Detrimental | High CCL22 levels associated with recruitment of T<sub>reg</sub> cells and poor disease outcome | 54  |
| CCL28        | HGSOC     | III, IV            | 88         | IHC        | Detrimental | High CCL28 levels associated with recruitment of T<sub>reg</sub> cells and poor disease outcome | 61  |
| CXCL9, CXCL10| HGSOC     | III, IV            | 184        | IHC        | Beneficial | High CXCL9 and CXCL10 levels associated with recruitment of effector CD8<sup>+</sup> T cells and favorable prognosis | 70  |
| CXCL12       | HGSOC     | III, IV            | 53         | IHC IF     | Detrimental | High CXCL12 levels correlated with angiogenesis, increased infiltration of myeloid cells and poor disease outcome | 156 |
|             | HGSOC, EnOC| All                | 44         | IHC        | Detrimental | High CXCR4 expression correlated with cancer cells proliferation and poor disease outcome | 173 |
| CXCL13       | HGSOC     | All                | 264        | IHC, IF    | Beneficial | High CXCL13 levels correlated with recruitment of CXCR5<sup>+</sup>CD8<sup>+</sup> T cells in TLS and favorable disease outcome | 190 |
| CXCL16       | HGSOC     | All                | 60         | IHC        | Detrimental | High CXCR6 expression correlated with metastatic spread and poor disease outcome | 169 |
| CXCL17       | HGSOC     | n.a.               | n.a.       | RT-PCR     | Beneficial | High CXCL17 levels associated with recruitment of DCs and favorable disease outcome | 74  |
| **Metastatic lesion** |           |                    |            |            |          |         |
| IL-6         | EOC       | All                | 70         | Luminex    | Detrimental | High IL-6 levels in malignant ascites correlated with chemo-resistance and poor PFS | 168 |
|              | EOC       | All                | 31         | ELISA      | Detrimental | High IL-6 and IL-10 levels correlated with accumulation of CD14<sup>+</sup>HLA-DR MDSCs in malignant ascites and poor disease outcome | 111 |
|              | HGSOC     | III, IV            | 30         | ELISA      | Detrimental | High IL-6 levels correlated with accumulation of CD163<sup>+</sup>CD68<sup>+</sup> M2-like TAMs in malignant ascites and poor disease outcome | 65  |
| IL-10        | HGSOC     | III, IV            | 30         | ELISA      | Detrimental | High IL-10 levels correlated with M2-like TAMs polarization and poor prognosis | 65  |
genotoxic chemotherapies and RT can favor the formation and/or expression of mutated neoepitopes. However, expression levels may remain low and hence be incompatible with robust immune recognition. Chemotherapeutic agents used for the clinical management of platinum-resistant EOC, including doxorubicin, oxaliplatin and paclitaxel, are known to drive immunogenic cell death, which is associated with the abundant emission of immunostimulatory molecules commonly known as damage-associated molecular patterns (DAMPs) and thus might synergize with immunotherapy. In line with this notion, pegylated doxorubicin has been shown to boost the uptake of dying EOC cells by cDCs and ultimately promote the cross-priming of T cells specific to EOC-associated antigens. However, the combination of pegylated doxorubicin with an ICI specific for PD-L1 (avelumab) failed to demonstrate superior activity compared with standard of care in a recent phase III clinical trial. Similar findings have been documented in a randomized phase II study testing the combination of pegylated doxorubicin with a TLR 8 (TLR8) agonist (motolimod). In addition to promoting polyploidization and hence boosting the immunogenicity of EOC cells, paclitaxel promotes the repolarization of M2-like TAMs into their M1-like counterparts, as well as the depletion of T_reg cells and MDSCs from the ovarian TME. However, available preclinical data are insufficient to support the initiation of clinical trials testing paclitaxel in combination with ICIs in women with advanced EOC.

Metronomic cyclophosphamide has also been shown to deplete T_reg cells from the ovarian TME, suggesting some potential for synergy with immunotherapeutic regimens. In line with this notion, metronomic cyclophosphamide combined with an angiogenesis inhibitor and a PD-1-targeting ICI (pembrolizumab) is well tolerated and mediates clinical benefits in 95.0% and durable treatment responses (>12 months) in 25.0% of women with recurrent EOC.

**Immune checkpoint inhibitors.**

PD-1, CTLA-4, LAG3, TIM-3, and other coinhibitory receptors are widely expressed by EOC-infiltrating cells and mediate robust immunosuppressive effects. Thus, ICIs a priori represent a valid strategy to reverse local immunosuppression in women with EOC. However, comprehensive phenotypic and functional analyses of EOC-infiltrating T cells and the ovarian TME have revealed the existence of a multilayered immunosuppressive network, potentially explaining the poor clinical activity of ICIs documented so far in patients with EOC. Indeed, in the first phase II study evaluating the efficacy of a PD-1-targeting ICI (nivolumab) for recurrent EOC, the overall response rate (ORR) in 20 assessable patients was only 15%, with a 10% durable complete response rate. Similarly, the use of pembrolizumab as a single therapeutic agent for EOC has been linked to an ORR of 9%, which was primarily associated with increased expression of PD-L1.

---

**Table 3 Continued**

| Histology | Stage | No of patients | Method | Impact | Note | Ref. |
|-----------|-------|----------------|--------|--------|------|-----|
| VEGF      | HGSOC III, IV | 56 | Microarray, IHC | Detrimental | High VEGF levels correlated with accumulation of MDSCs and poor disease outcome | 14 |
| TNFα      | EOC All | 70 | Luminex | Detrimental | High TNFα levels in malignant ascites correlated with chemoresistance and poor PFS | 168 |
| CCL18     | HGSOC III, IV | 53 | RT-PCR, ELISA, WB | Detrimental | High CCL18 levels correlated with cancer cells proliferation and metastatic spread | 174 |
| CCL22     | n.a. All | 70 | ELISA | Detrimental | High CCL22 levels correlated with recruitment of T_reg cells and poor disease outcome | 54 |
| CXCL12    | EOC III, IV | n.a. | ELISA, FC | Detrimental | High CXCL12 levels correlated with accumulation of MDSCs in malignant ascsites and poor disease outcome | 113 |

*Encompassing all EOC histological subtypes
CCL18, C-C motif chemokine ligand 18; CXCL12, C-X-C motif chemokine ligand 12; DC, dendritic cell; EnOC, endometrial ovarian cancer; EOC, epithelial ovarian carcinoma; FC, flow cytometry; HGSOC, high-grade serous ovarian carcinoma; IDO, indoleamine 2,3-dioxygenase; IF, immunofluorescence; IHC, immunohistochemistry; IL6, interleukin 6; MDSC, myeloid-derived suppressor cell; MOC, mucinous ovarian cancer; n.a., not available; OS, overall survival; PFS, progression-free survival; TAM, tumor associated macrophage; TGFβ, transforming growth factor; TLS, tertiary lymphoid structure; TNFα, tumor necrosis factor alpha; T_reg, regulatory T cell; VEGF, vascular endothelial growth factor; WB, western blotting.

| Histology | Stage | No of patients | Method | Impact | Note | Ref. |
|-----------|-------|----------------|--------|--------|------|-----|
| VEGF      | HGSOC III, IV | 56 | Microarray, IHC | Detrimental | High VEGF levels correlated with accumulation of MDSCs and poor disease outcome | 14 |
| TNFα      | EOC All | 70 | Luminex | Detrimental | High TNFα levels in malignant ascites correlated with chemoresistance and poor PFS | 168 |
| CCL18     | HGSOC III, IV | 53 | RT-PCR, ELISA, WB | Detrimental | High CCL18 levels correlated with cancer cells proliferation and metastatic spread | 174 |
| CCL22     | n.a. All | 70 | ELISA | Detrimental | High CCL22 levels correlated with recruitment of T_reg cells and poor disease outcome | 54 |
| CXCL12    | EOC III, IV | n.a. | ELISA, FC | Detrimental | High CXCL12 levels correlated with accumulation of MDSCs in malignant ascsites and poor disease outcome | 113 |
One potential approach to improving the efficacy of ICIs in patients with EOC relies on the use of multiple nonredundant ICIs as a combinatorial regimen.176 Supporting the validity of this approach, nivolumab combined with a CTLA-4-specific ICI (ipilimumab) has been associated with an ORR of 31.4% (vs 12.2% for nivolumab alone) in phase II clinical trials enrolling 100 patients with persistent or recurrent EOC.192 Based on these clinical findings and the preclinical data discussed above, current efforts are being refocused on targeting coinhibitory receptors other than CTLA-4 and PD-1, including (but not limited to) TIM-3, LAG3 and TIGIT (source https://clinicaltrials.gov). The results of these trials are urgently awaited.

**Angiogenesis inhibitors**

The anti-angiogenic drug bevacizumab, a humanized monoclonal antibody targeting VEGFA, has now been employed for first-line management of advanced EOC for more than 7 years.193 Based on preclinical findings from mouse models of EOC, bevacizumab is expected to synergize with ICIs, largely reflecting its ability to promote tumor infiltration by T cells.194 Consistent with this notion, bevacizumab in combination with nivolumab has been associated with improved ORR (28.9%) and PFS (median 9.4 months) in women with relapsed EOC, an activity that was even more pronounced in patients with platinum-sensitive lesions.195 Similarly, an ICI specific to PD-L1 (durvalumab) combined with a PARP inhibitor (olaparib) and cediranib, a tyrosine kinase inhibitor with anti-angiogenic activity, achieved an ORR of 50% and a disease control rate of 75% in 12 randomized patients.196 However, the results from a recent phase III study evaluating the addition of atezolizumab (an ICI specific for PD-L1) to platinum-based chemotherapy and bevacizumab failed to support the use of ICIs for newly diagnosed stage III or IV EOCs.197

---

**Figure 2** Cytokines and chemokines that coordinate the tumor microenvironment. Primary cytokines (A) and chemokines (B) produced in the ovarian tumor microenvironment. The most prominent sources and major receptors are depicted. CCL, chemokine (C-C motif) ligand; CCR, C-C chemokine receptor; CXCL, chemokine (C-X-C motif) ligand; CXCR, C-X-C chemokine receptor; CTL, cytotoxic T lymphocyte; IL, interleukin; IL6R, interleukin 6 receptor; MDSC, myeloid-derived suppressor cell; NK, natural killer; pDC, plasmacytoid dendritic cell; TAM, tumor-associated macrophage; TGFβ1, transforming growth factor beta 1; TGFBR, transforming growth factor beta receptor; TNF, tumor necrosis factor; TNFR, tumor necrosis factor receptor; TREG, regulatory T; VEGFA, vascular endothelial growth factor A; VEGFR, vascular endothelial growth factor receptor.
PARP inhibitors

PARP inhibitors have emerged as key therapeutic interventions for patients with EOC. Indeed, rather common germline mutations in BRCA1 and BRCA2, resulting in HR defects, make EOCs highly sensitive to PARP inhibitors. Thus, no less than three distinct PARP inhibitors (ie, niraparib, olaparib, and rucaparib) are currently approved for the treatment of recurrent, platinum-sensitive EOC as maintenance on platinum chemotherapy. Of note, PARP inhibitors have been shown to mediate multipronged immunostimulatory effects, largely reflecting their ability to inhibit DNA repair in malignant cells, and indicating the possibility for synergy with ICIs. Thus, PARP inhibitors might enhance the mutational load of EOCs as consequence of unrepaired DNA damage, favoring T cell infiltration, but also appear to drive robust type I IFN secretion downstream of cyclic GMP-AMP synthase and stimulator of IFN response cGAMP interactor 1 activation. Based on these preclinical findings, PARP inhibitors are currently being tested in combination with ICIs in more than 10 ongoing clinical trials. The results of this wave of investigation are highly anticipated.

Tumor vaccines

A variety of tumor-associated antigens (TAAs) that can be specifically targeted by vaccination strategies have been identified in EOC. Cancer/testis antigen 1B (CTAG1B, best known as NY-ESO-1) is one such antigen, and several NY-ESO-1-based vaccines have been shown to provide NY-ESO-1 EOC patients with an OS advantage. However, vaccine-driven immunoeediting may ultimately promote the selection of NY-ESO-1 EOC cell clones and hence enable clinical relapse. An alternative approach for vaccination involves the use of mutated TAAs as targets. Although advantageous in some aspects, this approach does not circumvent the possible emergence of antigen-negative malignant cell clones, indicating an advantage for vaccination strategies targeting multiple TAAs at the same time, such as DC-based vaccines. In this context, DCs from a patient with EOC must be provided either ex vivo or in vivo with a source of TAAs in the context of activation cues in the former setting followed by DC reinfusion into the patient. Such sources can be as diverse as recombinant full-length TAAs or epitopes thereof, TAA-encoding nucleic acids, autologous tumor lysates, and allogeneic cancer cell lysates. Results from a number of clinical trials testing ex vivo DC-based vaccines in women with EOC demonstrate that this approach is well tolerated and associated with at least some activity. Moreover, in consideration of their mechanism of action, DC-based vaccines are expected to synergize with other immunotherapeutic interventions, such as ICI-based immunotherapy and adoptive T cell transfer (ACT).

Adoptive T cell transfer

ACT represents a personalized immunotherapy based on autologous TILs expanded ex vivo and reintroduced into patients together with high-dose IL-2 on lymphodepletion. ACT has demonstrated considerable potency in patients with metastatic melanoma but limited success in women with EOC, potentially due to the strong immunosuppressive networks at play in the ovarian TME or suboptimal TIL expansion ex vivo. Several pilot and phase I/II clinical studies are currently open to investigating the therapeutic profile of ACT in women with advanced EOC. That said, available results from a pilot study enrolling six patients with advanced EOC suggest that ACT is primary active on existing target lesions but fails to control distant progression, potentially linked to TIL exhaustion, insufficient expansion or intralesional/interlesion heterogeneity.

Chimeric antigens receptor-T cells and TCR therapy

Chimeric antigens receptors (CARs) are fusion proteins engineered into T cells for them to recognize specific antigens independent on MHC presentation. CAR-T cell therapy has achieved unprecedented success in the treatment of hematological malignancies such as relapsed/refractory B-cell leukemia and lymphoma. However, a similar success has not been witnessed in patients with solid tumors, due to variety of obstacles. In line with this notion, a phase I study evaluating the safety and efficacy of first-generation of CAR-T cells targeting the folate receptor alpha (FOLR1) in patients with metastatic EOC documented limited efficacy. Current efforts are focusing on increasing CAR-T cell potency, with a particular interest around promoting CAR-T cells infiltration and intratumoral persistence. Despite these and other limitations, numerous early phase clinical trials are currently testing CAR-T cells with a variety of specificities in women with EOC (source https://www.clinicaltrials.gov). In this setting, a recent case report documented some therapeutic benefit (partial response and inhibition of hepatic progression) in a patient with metastatic EOC receiving CAR-T cells targeting mesothelin (MSLN) and engineered to secrete a PD-1-blocking single-chain fragment in combination with apatinib. These results suggest a novel therapeutic strategy for EOC and a Phase I study investigating this possibility is ongoing (NCT04503980). In similar line, T cells engineered by viral vectors to express the TCR gene with defined specificity (TCR-T cells) targeting NY-ESO-1 (NCT01567891, NCT03017131), MUC16 (NCT02498912), MAGE-A4 (NCT03132922) and neoantigens (NCT03418877) are tested in early phase clinical studies in EOC patients.

Oncolytic virus therapy

An alternative strategy to resolve immunosuppression is administer oncolytic viruses (OVs) directly into the TME. OVs preferentially infect and replicate in malignant cells, culminating with cell lysis accompanied by the release of various cytokines and DAMPs in support...
of tumor-targeting immunity. Indeed, talimogene laherparepvec (T-VEC)—the first OV approved by the US Food and Drug Administration—mediated multiple immunomodulatory functions, including the GM-CSF-dependent recruitment, maturation, and activation of APCs culminating with the initiation of robust T cell responses with systemic outreach. Along similar lines, the oncolytic adenovirus AD5/3 has recently been shown to restore immunostimulation in the EOC microenvironment along with increased infiltration by CTLs. Therefore, OVs represent a promising combinatorial partner for other immunotherapeutic regimens in the management of solid tumors including EOC. For instance, T-VEC in combination with ICIs showed promising results in early phase clinical trials enrolling melanoma patients.

### Table 4  Potential immunotherapeutic strategies against ovarian carcinoma

| TMB status | Immune contexture | Vascularity | Potential immunotherapy |
|------------|------------------|-------------|-------------------------|
| High       | High             | Low         | ICIs                    |
| High       | High             | High        | ICIs + antiangiogenic agents |
| High       | Low              | Low         | PARPi + antiangiogenic agents |
| Low        | Low              | Low         | Immunogenic chemotherapy + DC-based therapy |
| Low        | Low              | Low         | T-cell-based therapies (CAR-T cells, TILs) |
| Low        | Low              | Low         | Vaccines (DC-based therapy) |
| Low        | Low              | Low         | PARPs + ICIs            |

CAR-T cell, chimeric antigen receptor T cell; DC, dendritic cell; ICI, immune checkpoint inhibitor; PARPi, poly (ADP-ribose) polymerase inhibitor; TILs, tumor-infiltrating lymphocytes; TMB, Tumor mutational burden.

CONCLUDING REMARKS

Immunotherapy with ICIs has revolutionized the management of multiple tumor types, creating enormous expectations around the possibility of harnessing the patient immune system against EOC. However, the clinical benefit of ICIs as standalone immunotherapeutic interventions in women EOC is limited. This may reflect limited pre-existing immunity and/or the existence of robust immunosuppressive pathways in the EOC microenvironment.

In line with this notion, the findings discussed herein demonstrate that pre-existing immunity in the ovarian TME has a major impact on the sensitivity of EOC to (immuno)therapy, calling for the identification of immune biomarkers to integrate into common diagnostic assessments and guide treatment selection (table 4). For instance, women with highly infiltrated EOCs (so-called ‘hot’ tumors with an elevated immunoscore) may benefit from ICI-based immunotherapy or ACT, whereas individuals with an intermediate degree of immune infiltration are expected to respond to agents that stimulate CD8+ T cell infiltration (table 4). So-called ‘cold’ tumors which are characterized by a low immunoscore, remain the most challenging to eradicate and hence are associated with poor prognosis.

A potential strategy to overcome the lack of pre-existing immunity in EOC is to combine a priming therapy that enhances T cell responses, such as DC-based vaccination, or strategies that turn the tumor into an in situ vaccine, such as RT, using an approach that either removes immunosuppressive cues (eg, ICI-based immunotherapy, TAM depletion) or provides immunostimulatory signals. Moreover, accumulating preclinical and clinical evidence indicates that epigenetic modifiers, including DNA demethylating agents and some chemotherapeutics, can stimulate antitumor immunity by various mechanisms, including the (1) selective deletion of immunosuppressive cells; (2) lymphodepletion associated with renovation of the patient immunological repertoire and (3) activation of immune effector cells and hence may be beneficial in patients with low or absent TILs (table 4).

Similarly, immunogenic chemotherapeutics such as doxorubicin and paclitaxel, antiangiogenic drugs and PARP inhibitors stand out as promising partners for ICIs in the management of patients with ‘cold’ EOC.

We surmise that rationally designed combinations of conventional and immunotherapeutic agents will be critical to unlock immunosuppression in the EOC microenvironment in support of clinical efficacy. Preclinical studies in immunocompetent EOC identifying not only the agents to be used in such combinations, but also their optimal administration schedule are urgently required to translate an expanding literature on the immune contexture of EOC into clinically relevant therapeutic strategies.

Author affiliations

1Sotio Biotech, Prague, Czech Republic
2Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
3Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
4UCLA David Geffen School of Medicine and Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA
5Gynecologic Oncology Center, Department of Obstetrics and Gynecology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
6Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospital Leuven, Leuven, Belgium
7Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
8Sandra and Edward Meyer Cancer Center, New York, NY, USA
REFERENCES

1 Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin 2021;71:7–33.
2 Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 2019;30:672–705.
3 Mlinic K, Köbel M, Kalloger SE, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD205, FOXP3 and TIA-1 as positive prognostic factors. PLoS One 2009;4:e6412.
4 Zhou J, Wu S-G, Wang J, et al. The effect of histological subtypes on outcomes of stage IV epithelial ovarian cancer. Front Oncol 2018;8:577.
5 Hu Z, Artibani M, Alsaadi A, et al. The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. Cancer Cell 2020;37:226–42.
6 Gonzalez-Vélez, Samuskis N, Chen TJ, et al. Commonly occurring cell subsets in high-grade serous ovarian tumors identified by single-cell mass cytometry. Cell Rep 2018;22:1875–88.
7 Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22:620–631.
8 Galluzzi L, Chan TA, Kroemer G, et al. The hallmarks of successful anticancer immunotherapy. Sci Transl Med 2018;10. doi:10.1126/ scitranslmed.aat7807. [Epub ahead of print: 19 Sep 2018].
9 Kandalaft LE, Odunsi K, Coukos G. Immunotherapy in ovarian cancer: are we there yet? J Clin Oncol 2019;37:2460–71.
10 Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 2018;17:197–218.
11 Hamanishi J, Mandal M, Ikeda T, et al. Safety and antitumor activity of anti-CD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015;33:4015–22.
12 Yang Y, Yang Y, Yang J, et al. Tumor microenvironment in ovarian cancer: function and therapeutic strategy. Front Cell Dev Biol 2020;8:758.
36. Santoimma PP, Reyes C, Wang L-P, et al. Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. *Gynecol Oncol* 2016;143:120–7.

37. Hermans C, Arntz D, Engel J, et al. Analysis of Foxp3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers. *PLoS One* 2014;9:e111757.

38. Barnett JC, Bean SM, Whitaker RS, et al. Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. *Gynecol Oncol* 2010;116:556–62.

39. Henricksen JR, Donskov F, Waldstrom M, et al. Favorable prognostic impact of natural killer cells and T cells in high-grade serous ovarian carcinoma. *Acta Oncol* 2020;59:652–9.

40. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. *N Engl J Med* 2003;348:203–13.

41. Clarke B, Tinker AV, Lee C-H, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. *Mod Pathol* 2009;22:393–402.

42. Zhang Z, Huang J, Zhang C, et al. Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer. *Cancer Gene Ther* 2015;22:198–206.

43. Lieber S, Reintz S, Raffer H, et al. Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites. *CXCL9 levels and activation-triggered signal transduction in T cells*. *Oncimmunology* 2018;7:e1424672.

44. Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, et al. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian carcinoma. *JAMA Oncol* 2017;3:173290. doi:10.1001/jamaoncol.2017.3290.

45. Fucikova J, Rakova J, Hensler M, et al. Tim-3 dictates functional orientation of the immune infiltrate in ovarian cancer. *Clin Cancer Res* 2019;25:4820–37.

46. Facciabene A, Motz GT, Fialová A, Partlová S, Sojka L, et al. Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. *Int J Cancer* 2013;132:1070–9.

47. Zhou J, Li X, Wu X, et al. Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg/Th17 cell imbalance in epithelial ovarian cancer. *Cancer Immunol Res* 2018;6:1578–92.

48. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. *Nature* 2011;475:226–30.

49. Toker A, Nguyen LT, Stone SC, et al. Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma. *Clin Cancer Res* 2018;24:5685–96.

50. WucleK SK, Cueto FJ, Mualj AM, et al. Dendritic cells in cancer immunology and immunotherapy. *Nat Rev Immunol* 2020;20:7–24.

51. Martinke J, Wu T-C, Cadena D, et al. Interplay between dendritic cells and cancer cells. *Int Rev Cell Mol Biol* 2019;348:179–215.

52. Reintz S, Schumann T, Finkernagel F, et al. Mixed-polarization phenotype of ascs-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. *Int J Cancer* 2014;134:32–42.

53. Wu M, Chen X, Lou J, et al. TGF-β1 contributes to CD8+ T cell induction through p38 MAPK signaling in ovarian cancer microenvironment. *Oncotarget* 2016;7:44534–44.

54. Cai DL, Jin L-P. Immune cell population in ovarian tumor microenvironment. *J Cancer* 2017;8:2915–23.

55. Chen F, Hou M, Ye F, et al. Ovarian cancer cells induce peripheral mature dendritic cells to differentiate into macrophagelike cells in vitro. *Int J Gynecol Cancer* 2009;19:1487–93.

56. Curiel TJ, Wei S, Dong H, et al. Blockade of B7–H1 improves myeloid dendritic cell-mediated antitumor immunity. *Nat Med* 2003;9:562–7.

57. Bronger H, Singer J, Windmüller C, et al. Cxcl9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. *Br J Cancer* 2016;115:553–63.

58. Amon L, Lehmann CHK, Baraniska A, et al. Transcriptional control of dendritic cell development and functions. *Int Rev Cell Mol Biol* 2019;349:55–151.

59. Broz ML, Binniewies M, Boldajipour B, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. *Cancer Cell* 2014;26:938.

60. Sauvé-Fridman C, Petitpres F, Calderaro J, et al. Lymphoid tissue structures in the era of cancer immunotherapy. *Nat Rev Cancer* 2019;19:307–25.

61. MacGregor HL, Garcia-Batres C, Sayad A, et al. Tumor cell expression of B7–H4 correlates with higher frequencies of tumor-infiltrating AREG and high CXCL17 expression in human epithelial ovarian cancer. *Oncimmunology* 2019:8:e1665460.

62. Leylek R, Idoyaga J. The versatile plasmacytoid dendritic cell: function, heterogeneity, and plasticity. *Int Rev Cell Mol Biol* 2018;349:177–219.

63. Demoulin S, Herds M, Delvenne P, et al. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. *J Leukoc Biol* 2013;93:343–52.

64. Labidi-Galy S, Sisirak V, Meeus P, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. *Cancer Res* 2011;71:5423–34.

65. Inaba T, Ino K, Kajiyama H, et al. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian cancer. *Gynecol Oncol* 2009;115:182–9.

66. Zou W, Machelon V, Coulomb-L’Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. *Nat Med* 2001;7:1339–46.

67. Fucikova J, Palova-Jelinkova L, Bartunkova J, et al. Induction of tolerance and immunity by dendritic cells: mechanisms and clinical applications. *Front Immunol* 2019;10:2393.

68. Nielsen JS, Sahota RA, Milne K, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T-cells promote favorable prognosis in ovarian cancer. *Clin Cancer Res* 2012;18:3281–94.

69. Iglesias MD, Vincent BG, Parker JS, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. *Clin Cancer Res* 2014;20:3818–29.

70. Kroeger DR, Milne K, Nelson BH. Tumor-Infiltrating plasma cells are associated with tertiary lymphoid structures, cytotoxic T-cell responses, and superior prognosis in ovarian cancer. *Clin Cancer Res* 2016;22:3005–15.

71. Zhu Y, Zhang Z, Jiang Z, et al. Cd38 predicts favorable prognosis by enhancing immune infiltration and antitumor immunity in the epithelial ovarian cancer microenvironment. *Front Genet* 2020;11:369.

72. Lundgren S, Berntsson J, Nodin B, et al. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. *J Ovarian Res* 2016;9:21.

73. Jelinkova L, Bartunkova J, et al. Tumor hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. *Nature* 2011;475:226–30.

74. Niessl JS, Sahota RA, Milne K, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T-cells promote favorable prognosis in ovarian cancer. *Clin Cancer Res* 2012;18:3281–94.

75. Iglesias MD, Vincent BG, Parker JS, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. *Clin Cancer Res* 2014;20:3818–29.

76. Kroeger DR, Milne K, Nelson BH. Tumor-Infiltrating plasma cells are associated with tertiary lymphoid structures, cytotoxic T-cell responses, and superior prognosis in ovarian cancer. *Clin Cancer Res* 2016;22:3005–15.

77. Zhu Y, Zhang Z, Jiang Z, et al. Cd38 predicts favorable prognosis by enhancing immune infiltration and antitumor immunity in the epithelial ovarian cancer microenvironment. *Front Genet* 2020;11:369.
Germain C, Gnjatic S, Tarzamali F, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. *Am J Respir Crit Care Med* 2014;189:832–44.

Fukison BH. CD20 B cells: the other tumor-infiltrating lymphocytes. *J Immunol* 2010;185:4977–82.

Montfort A, Pearce O, Maniatil E, et al. A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. *Clin Cancer Res* 2017;23:250–62.

Vitale I, Shama E, Loi S, et al. Intratumoral heterogeneity in cancer progression and response to immunotherapy. *Nat Metab* 2021;27:212–24.

Vankercykhoen A, Wouters R, Mathivet T, et al. Opposite macrophage polarization in different subsets of ovarian cancer: observation from a pilot study. *Cells* 2020;9; doi:10.3390/cells9020305. [Epub ahead of print: 27 Jan 2020].

Vitale I, Manic G, Coussens LM, et al. Macrophages and metabolism in the tumor microenvironment. *Cell Metab* 2019;30:36–50.

Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. *Nat Rev Drug Discov* 2018;17:879–904.

Yin M, Li X, Tan S, et al. Tumor-Associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. *J Clin Invest* 2016;126:4157–73.

Yuan X, Zhang J, Li D, et al. Prognostic significance of tumor- associated macrophages in ovarian cancer: a meta-analysis. *Gynecol Oncol* 2017;147:181–7.

Le Page C, Marineau A, Bonza PK, et al. BTNSA2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. *PLoS One* 2012;7:e38541.

Lan C, Huang X, Lin S, et al. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. *Technol Cancer Res Treat* 2013;12:259–67.

He Y-feng, Zhang M-xing, Wu X, et al. High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time. *PLoS One* 2013;8:e79769.

Hagemann T, Robinson SC, Thompson RG, et al. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. *Mol Cancer Ther* 2007;6:1993–2002.

Zhou Y, Xu Y, Chen L, et al. B7-H6 expression correlates with cancer progression and patient’s survival in human ovarian cancer. *J Ovarian Res* 2014;7:19.

Macciò A, Gramignano G, Cherubini F, et al. Role of M1-polarized tumor-associated macrophages in the progression of advanced ovarian cancer patients. *Sci Rep* 2020;10:6096.

Guerriero JL. Macrophages: their untold story in T cell activation and function. *Int Rev Cell Mol Biol* 2019;342:73–93.

Gharpure KM, Pradeep S, Sans M, et al. Fabp4 as a key determinant of metastatic potential of ovarian cancer. *Nat Commun* 2018;9:2923.

Hao J, Yan F, Zhang Y, et al. Expression of Adipocyte/Macrophage fatty acid-binding protein in tumor-associated macrophages promotes breast cancer progression. *Cancer Res* 2018;78:2343–55.

Nieman KM, Kenny HA, Penicka CV, et al. Expression of M2-polarized macrophages and MET amplification are independent predictors of poor survival in advanced ovarian cancer. *PLoS One* 2016;4:303–11.

Macciò A, Gramignano G, Cherubini F, et al. Expression of M2-polarized macrophages and MET amplification are independent predictors of poor survival in advanced ovarian cancer. *PLoS One* 2016;4:303–11.

Boschini F, Neri M, di Prisco F, et al. High expression of MUC2 and MUC1 in ovarian cancer is associated with poor prognosis. *Nat Commun* 2013;4:2976.

Boschini F, Neri M, di Prisco F, et al. High expression of MUC2 and MUC1 in ovarian cancer is associated with poor prognosis. *Nat Commun* 2013;4:2976.

Yin Y, He X, Zhang X, et al. Expression of high MUC2 in ovarian cancer patients. *Sci Rep* 2016;6:30311.

Macciò A, Gramignano G, Cherubini F, et al. Expression of M2-polarized macrophages and MET amplification are independent predictors of poor survival in advanced ovarian cancer. *PLoS One* 2016;4:303–11.

Gharpure KM, Pradeep S, Sans M, et al. Fabp4 as a key determinant of metastatic potential of ovarian cancer. *Nat Commun* 2018;9:2923.

Hao J, Yan F, Zhang Y, et al. Expression of Adipocyte/Macrophage fatty acid-binding protein in tumor-associated macrophages promotes breast cancer progression. *Cancer Res* 2018;78:2343–55.

Nieman KM, Kenny HA, Penicka CV, et al. Expression of M2-polarized macrophages and MET amplification are independent predictors of poor survival in advanced ovarian cancer. *PLoS One* 2016;4:303–11.

Boschini F, Neri M, di Prisco F, et al. High expression of MUC2 and MUC1 in ovarian cancer is associated with poor prognosis. *Nat Commun* 2013;4:2976.

Boschini F, Neri M, di Prisco F, et al. High expression of MUC2 and MUC1 in ovarian cancer is associated with poor prognosis. *Nat Commun* 2013;4:2976.
fibrovascular network expansion and tumor progression. PLoS One 2009;4:e4992.
137 McLean K, Gong Y, Choi Y, et al. Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest 2011;121:3508–15.
138 Mhawech-Fauceglia P, Wang D, Samroa D, et al. Clinical implications of marker expression of carcinoma-associated fibroblasts (CAFs) in patients with epithelial ovarian carcinoma after treatment with neoadjuvant chemotherapy. Cancer Microenviron 2014;7:33–9.
139 Sun Y, Fan X, Zhang Q, et al. Cancer-Associated fibroblast secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling. Tumor Biol 2017;39:1010426317712592.
140 Vitale I, Manic G, Gallassi C, et al. Stress responses in stromal cells and tumor homeostasis. Pharmacol Ther 2019;200:55–68.
141 Schauer IG, Sood AK, Mok S, et al. Cancer-Associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 2011;13:393–405.
142 Schauer IG, Zhang J, Xing Z, et al. Interleukin-1β promotes ovarian tumorigenesis through a p38/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia 2013;15:409–20.
143 Mitra AK, Zillhardt M, Hua Y, et al. Micromas reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov 2012;2:1100–8.
144 Curtis M, Kenny HA, Ashcroft B, et al. Fibroblasts mobilize tumor cell glycogen to promote proliferation and metastasis. Cell Metab 2019;29:141–55.
145 Tsukishiro S, Suzumori N, Nishikawa H, et al. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. Gynecol Oncol 2006;102:542–5.
146 Yeung T-L, Leung CS, Wong K-K, et al. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res 2013;73:2016–28.
147 Orimo A, Gupta PS, Groll W, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335–48.
148 Ladanyi A, Mukherjee A, Kenny HA, et al. Adipocycte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene 2018;37:2285–301.
149 Leung CS, Yeung T-L, Yip K-P, et al. Cancer-Associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest 2018;128:589–606.
150 Yan H, Guo B-Y, Zhang S, Cancer-Associated fibroblasts attenuate cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling. Biochim Biophys Acta 2016;1748:947–54.
151 Monteran L, Erez N. The dark side of fibroblasts: cancer-stromal interactions. Acta Oncol 2017;56:1010–24.
152 Lakins MA, Ghori E, Munir H, et al. Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T Cells to protect tumour cells. Nat Commun 2018;9:948.
153 Ko SY, Barengo N, Ladanyi A, et al. Hoxa11 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest 2012;122:3603–17.
154 Li W, Zhang X, Wang J, et al. Tgfβ1 in fibroblasts-derived exosomes promotes epithelial-mesenchymal transition of ovarian cancer cells. Oncotarget 2017;8:96035–47.
155 Zsiores E, Duttagupta P, Danag D, et al. The ovarian cancer chemokine landscape is conducive to homing of Vaccine-Primed and CD3/CD28-Costimulated T cells prepared for adoptive therapy. Clin Cancer Res 2015;21:2840–50.
156 Kulhe H, Chakravarty P, Leinster DA, et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Discov 2017;7:66–75.
157 Coward J, Kulhe H, Chakravarty P, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011;17:6083–96.
158 Nilsson MB, Langley RR, Figler IJ, et al. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005;65:10794–800.
159 Isobe A, Sawaida K, Kinose Y, et al. Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer. PLoS One 2015;10:e0118080.
160 Behrending L, Pasinetti, Horvath EB, et al. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manag Res 2018;10:6685–93.
161 Saiot U, Naidu S, ElNaggar AC, et al. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene 2017;36:168–81.
162 Colomerie M, Ward AC, Riley C, et al. Cross talk of signals between EGFR and α6β4 integrin promotes epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 2009;100:134–44.
163 Alsinas-Sanchis E, Figueras A, Lahiguera Álvaro, et al. The TGFβ3 pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels. Int J Cancer 2016;138:1891–903.
164 Kassim SK, El-Salahy EM, Fayed ST, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004;37:363–9.
165 Charles KA, Kulhe H, Soper R, et al. The tumor-promoting actions of TNF-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol Oncol 2015;138:352–7.
166 Mir H, Kaur G, Kapur N, et al. Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation. Sci Rep 2017;7:2527.
167 Negus RP, Stamp GW, Reif MG, et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995;95:2391–6.
168 Nesbath YC, Martinez DG, Toraya S, et al. Cd4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J Immunol 2010;184:5654–62.
169 Franciszkiewicz K, Boutel M, Gauthier L, et al. Synthetic release of CCL5 storage vesicles triggers CXCR4 surface expression promoting CTL migration in response to CXCL12. J Immunol 2014;10:4952–61.
170 Jiang Y-P, Wu X-H, Shi B, et al. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol 2006;103:226–33.
171 Lane D, Matte I, Laplante C, et al. Ccl18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling. Mol Cancer 2016;15:58.
172 Wang Q, Tang Y, Yu H, et al. Ccl18 from tumor cells promotes ovarian epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog 2015;65:1888–99.
173 Huang R-Y, Francois A, McGray AR, et al. Compensatory upregulation of PDL-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology 2017;6:e124561.
174 Sha D, Jin Z, Budczies J, et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov 2020;10:1808–25.
175 Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol 2020;17:725–41.
176 Lhuiller C, Rudqvist N, et al. Calreticulin exposure definition, detection and interpretation of immunogenic cell death. J Immunother Cancer 2021;9:e002873. doi:10.1136/jitc-2021-002873 on 13 October 2021. Downloaded from https://jitc.bmj.com/ on September 16, 2023 by guest. Protected by copyright.
Monk BJ, Brady MF, Aghajanian C, et al. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimid with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partnered study. Ann Oncol 2017;28:996–1004.

Senovilla L, Vitale I, Martins I, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012;337:1678–84.

Wanderley CW, Colón DF, Luiz JP, et al. Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in TLR4-dependent manner. Cancer Res 2018;78:5981–900.

Noordam L, Kaijen MEH, Bezemer K, et al. Low-Dose cyclophosphamide depletes circulating naive and activated regulatory T cells in malignant pleural mesothelioma patients synergistically acted with dendritic cell-based immunotherapy. Oncology 2018;97:e1474318.

Zsíros E, Lynam S, Attwood KM, et al. Efficacy and safety of pembrolizumab in combination with bevazumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol 2021;7:78–85.

Yang M, Lu J, Zhang G, et al. Cxcl13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. J Immunother Cancer 2021;9.

Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 Study. Ann Oncol 2019;30:1080–7.

Zamarri D, Burger RA, Still MW, et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study. J Clin Oncol 2020;38:1814–23.

Rossi L, Verboon H, Zaccarelli E, et al. Bevacizumab in ovarian cancer: a critical review of phase III studies. Oncotarget 2017;8:12389–405.

Shirriki RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010;70:6171–80.

Liu JF, Herold C, Gray KP, et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial. JAMA Oncol 2019;5:1731–8.

Lee J-M, Chimino-Mathews A, Peer CJ, et al. Safety and clinical activity of the programmed Death-Ligand 1 inhibitor Durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women’s cancers: a dose-escalation, phase I study. J Clin Oncol 2017;35:2193–202.

Moore KN, Bookman M, Sehoul J, et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMAgIn050/GOG 3015/ENGOT-OV39). J Clin Oncol 2021;39:1842–55. doi:10.1200/JCO.21.00306.

Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:2154–64.

Petroni G, Buqué A, Zitvogel L, et al. Immunomodulation by targeted anticancer agents. Cancer Cell 2021;39:310–45.

Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-Arm phases 1 and 2 trial of Niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2019;5:1141–9.

Yamazaki T, Kirchmair A, Sato A, et al. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nat Immunol 2020;21:1160–71.

Chabanon RM, Muirhead G, Krastev DB, et al. Parp inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J Clin Invest 2019;129:1211–28.

Sprooten J, Ceusters J, Coosemans A, et al. Trial Watch: dendritic cell vaccination for cancer immunotherapy. Oncology 2019;8:e1638212.

Oduseni K, Matsumaki J, James SR, et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res 2014;2:37–49.

Chow S, Beltisis J, Dorigo O. Development of therapeutic vaccines for ovarian cancer. Vaccines 2020;8. doi:10.3390/vaccines8040657. [Epub ahead of print: 05 Nov 2020].

Zhang X, He T, Li Y, et al. Dendritic cell vaccines in ovarian cancer. Front Immunol 2020;11:513773.

Fucà G, Reppel L, Lajuv E, et al. Enhancing dendritic cell therapy in solid tumors with immunomodulating conventional treatment. Mol Ther Oncolytics 2019;13:67–81.

Overwijk WW, Theoret MR, Finkelman SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569–80.

Westergaard MC, Andersen R, Chong C, et al. Tumour-reactive T cell subsets in the microenvironment of ovarian cancer. Br J Cancer 2019;120:424–34.

Petersen M, Westergaard MC, Milne K, et al. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. Oncology 2018;7:e1502905.

Zhang AW, McPherson A, Milne K, et al. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell 2018;173:1755–69.

Wagner DL, Fritsche E, Pulsipher MA, et al. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol 2021;18:379–93.

Liu G, Rui W, Zhao X, et al. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol 2021;18:1085–95.

Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:5106–15.

Fucà G, Reppel L, Lajuv E, et al. Enhancing chimeric antigen receptor T-cell efficacy in solid tumors. Clin Cancer Res 2020;26:2444–51.

Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 2020;17:147–67.

Fang J, Ding N, Guo X, et al. IpPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib. J Immunother Cancer 2021;9:e001162.

Pauwels M, Macirowski D. Advancing oncolytic virus therapy by understanding the biology. Nat Rev Clin Oncol 2021;18:197–8.

Andtbacka RH, Collicchio F, Harrington KJ, et al. Final analyses of OPTIM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer 2019;7:145.

Santos JM, Heinö K, Cervera-Carrascón V, et al. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-inhibiting lymphocyte tumor reactivity. J Immunother Cancer 2020;8:e001188.

Chesney J, Puzanov I, Collicchio F, et al. Randomized, open-label phase II study evaluating the efficacy of lenalidomide in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2018;4:1658–67.

Petroni G, Galluzzi L. Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents. Oncology 2021;10:1889101.

Wang L, Zhang F, Cui J, et al. CAFs enhance paclitaxel resistance by inducing EMT through the IL-6/JAK2/STAT3 pathway. Oncol Rep 2018;39:2081–90.